{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "9d2ed9ab-c78b-4d67-8b9b-18d22e44444b",
   "metadata": {},
   "source": [
    "# Variant annotation tables & direction of effect investigation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "id": "c6f9476d-828f-4ff7-82df-e2830b3e2767",
   "metadata": {
    "pycharm": {
     "name": "#%%\n"
    }
   },
   "outputs": [],
   "source": [
    "import os\n",
    "import csv\n",
    "import re\n",
    "from collections import Counter\n",
    "\n",
    "import pandas as pd\n",
    "\n",
    "from opentargets_pharmgkb.evidence_generation import ID_COL_NAME\n",
    "from opentargets_pharmgkb.pandas_utils import read_tsv_to_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "e6a46840-39c0-4518-8a05-9258568cda20",
   "metadata": {
    "pycharm": {
     "name": "#%%\n"
    }
   },
   "outputs": [],
   "source": [
    "pd.set_option('display.max_columns', None)\n",
    "pd.set_option('display.max_rows', 100)\n",
    "pd.set_option('display.max_colwidth', None)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "bf50f6c5-0b82-41f7-932e-1b78c2dc22df",
   "metadata": {},
   "source": [
    "## 1. Initial data exploration"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "27861f6f-9343-4c44-be4f-4bf70e39eee4",
   "metadata": {
    "pycharm": {
     "name": "#%%\n"
    }
   },
   "outputs": [],
   "source": [
    "data_dir = '/home/april/projects/opentargets/pharmgkb/doe'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "6c87bbc9-4c87-40a0-84d5-de9249f50192",
   "metadata": {
    "pycharm": {
     "name": "#%%\n"
    }
   },
   "outputs": [],
   "source": [
    "# Download new data (2024-05-05)\n",
    "# !cd {data_dir}\n",
    "\n",
    "# !wget -q https://api.pharmgkb.org/v1/download/file/data/clinicalAnnotations.zip\n",
    "# !wget -q https://api.pharmgkb.org/v1/download/file/data/variantAnnotations.zip\n",
    "\n",
    "# !unzip -jq clinicalAnnotations.zip \"*.tsv\" -d {data_dir}\n",
    "# !unzip -jq variantAnnotations.zip \"*.tsv\" -d {data_dir}\n",
    "\n",
    "# !rm clinicalAnnotations.zip variantAnnotations.zip"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1cd29785-b1ff-4e7f-af3a-fd42d2fd3058",
   "metadata": {},
   "source": [
    "The variant annotations zip file contains 4 new tables, described in the readme as follows:\n",
    ">* **var_pheno_ann.tsv**: Contains associations in which the variant affects a phenotype, with or without drug\n",
    "information.\n",
    ">* **var_drug_ann.tsv**: Contains associations in which the variant affects a drug dose, response, metabolism, etc.\n",
    ">* **var_fa_ann.tsv**: Contains in vitro and functional analysis-type associations.\n",
    ">* **study_parameters.tsv**: Contains information about the study population size, biogeographical group and statistics\n",
    "for the variant annotations; this file is cross-referenced against the 3 variant annotation files.\n",
    "\n",
    "Study parameters table is interesting but feels out of scope for now at least, will ignore for the rest of the notebook."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "4d823e4f-3e41-4bc6-a1d3-003c6bd14898",
   "metadata": {
    "pycharm": {
     "name": "#%%\n"
    }
   },
   "outputs": [],
   "source": [
    "var_drug_ann = read_tsv_to_df(os.path.join(data_dir, 'var_drug_ann.tsv'))\n",
    "var_fa_ann = read_tsv_to_df(os.path.join(data_dir, 'var_fa_ann.tsv'))\n",
    "var_pheno_ann = read_tsv_to_df(os.path.join(data_dir, 'var_pheno_ann.tsv'))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f7c7bbdb-9a0f-45ba-ac34-4070b8f0dbdb",
   "metadata": {},
   "source": [
    "Questions to consider:\n",
    "* How many annotations?\n",
    "* What's the coverage of variant/haplotypes relative to clinical annotations?\n",
    "* What are the relevant fields?\n",
    "* What's the relationship between these annotations and clinical annotations?\n",
    "* Which of these columns has a controlled vocab vs. free text?\n",
    "* How do the different variant-level annotation sentences contribute to the overall clincial annotation sentences?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "0852d631-f8ff-4fa8-afe0-6b2599b0b9c7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "11901"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(var_drug_ann)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "64ac3c98-d1cf-48c1-8805-ecdc4530d649",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2009"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(var_fa_ann)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "b826596b-12e4-4095-b9f5-f07796f0e7d7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "13517"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(var_pheno_ann)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "d22115ea-56f6-404d-9839-c91c8ed74a89",
   "metadata": {
    "pycharm": {
     "name": "#%%\n"
    },
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Variant Annotation ID</th>\n",
       "      <th>Variant/Haplotypes</th>\n",
       "      <th>Gene</th>\n",
       "      <th>Drug(s)</th>\n",
       "      <th>PMID</th>\n",
       "      <th>Phenotype Category</th>\n",
       "      <th>Significance</th>\n",
       "      <th>Notes</th>\n",
       "      <th>Sentence</th>\n",
       "      <th>Alleles</th>\n",
       "      <th>Specialty Population</th>\n",
       "      <th>Metabolizer types</th>\n",
       "      <th>isPlural</th>\n",
       "      <th>Is/Is Not associated</th>\n",
       "      <th>Direction of effect</th>\n",
       "      <th>PD/PK terms</th>\n",
       "      <th>Multiple drugs And/or</th>\n",
       "      <th>Population types</th>\n",
       "      <th>Population Phenotypes or diseases</th>\n",
       "      <th>Multiple phenotypes or diseases And/or</th>\n",
       "      <th>Comparison Allele(s) or Genotype(s)</th>\n",
       "      <th>Comparison Metabolizer types</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1451834452</td>\n",
       "      <td>CYP3A4*1, CYP3A4*17</td>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>nifedipine</td>\n",
       "      <td>15634941</td>\n",
       "      <td>Other, Metabolism/PK</td>\n",
       "      <td>not stated</td>\n",
       "      <td>in vitro expression of the recombinant CYP3A4*17 allelic protein and the wild-type protein</td>\n",
       "      <td>CYP3A4 *17 is associated with decreased metabolism of nifedipine as compared to CYP3A4 *1.</td>\n",
       "      <td>*17</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>decreased</td>\n",
       "      <td>metabolism of</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>*1</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1451159680</td>\n",
       "      <td>rs5031016</td>\n",
       "      <td>CYP2A6</td>\n",
       "      <td>warfarin</td>\n",
       "      <td>22248286</td>\n",
       "      <td>Dosage</td>\n",
       "      <td>no</td>\n",
       "      <td>No association was found between this variant and warfarin-maintenance dose. Described as CYP2A6*7 in this study.</td>\n",
       "      <td>Allele G is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele A.</td>\n",
       "      <td>G</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Not associated with</td>\n",
       "      <td>increased</td>\n",
       "      <td>dose of</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Other:an international normalized ratio (INR) of 2.0-3.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>A</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1451306860</td>\n",
       "      <td>CYP2C9*11</td>\n",
       "      <td>CYP2C9</td>\n",
       "      <td>warfarin</td>\n",
       "      <td>33350885</td>\n",
       "      <td>Dosage</td>\n",
       "      <td>not stated</td>\n",
       "      <td>\"This case suggests that CYP2C9 *11/*11 carriers require approximately two thirds less warfarin than CYP2C9\" normal function homozygotes.</td>\n",
       "      <td>CYP2C9 *11/*11 is associated with decreased dose of warfarin.</td>\n",
       "      <td>*11/*11</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>decreased</td>\n",
       "      <td>dose of</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>1448997750</td>\n",
       "      <td>CYP2B6*1, CYP2B6*18</td>\n",
       "      <td>CYP2B6</td>\n",
       "      <td>efavirenz</td>\n",
       "      <td>16495778</td>\n",
       "      <td>Metabolism/PK</td>\n",
       "      <td>yes</td>\n",
       "      <td>Please note that in the paper the allele was referred to as CYP2B6*16. CYP2B6*16 and *18 alleles have been consolidated by PharmVar in Jan 2020, with *16 now listed as a suballele of *18 (CYP2B6*18.002). This annotation is updated to be on CYP2B6*18, instead of CYP2B6*16.</td>\n",
       "      <td>CYP2B6 *1/*18 is associated with increased concentrations of efavirenz in people with HIV Infections as compared to CYP2B6 *1/*1.</td>\n",
       "      <td>*1/*18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>increased</td>\n",
       "      <td>concentrations of</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:HIV Infections</td>\n",
       "      <td>NaN</td>\n",
       "      <td>*1/*1</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>1448631821</td>\n",
       "      <td>CYP2C19*1, CYP2C19*2</td>\n",
       "      <td>CYP2C19</td>\n",
       "      <td>clomipramine, desmethyl clomipramine</td>\n",
       "      <td>28470111</td>\n",
       "      <td>Metabolism/PK</td>\n",
       "      <td>no</td>\n",
       "      <td>in a single individual</td>\n",
       "      <td>CYP2C19 *1/*2 is associated with increased trough concentration of clomipramine and desmethyl clomipramine.</td>\n",
       "      <td>*1/*2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>increased</td>\n",
       "      <td>trough concentration of</td>\n",
       "      <td>and</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  Variant Annotation ID    Variant/Haplotypes     Gene  \\\n",
       "0            1451834452   CYP3A4*1, CYP3A4*17   CYP3A4   \n",
       "1            1451159680             rs5031016   CYP2A6   \n",
       "2            1451306860             CYP2C9*11   CYP2C9   \n",
       "3            1448997750   CYP2B6*1, CYP2B6*18   CYP2B6   \n",
       "4            1448631821  CYP2C19*1, CYP2C19*2  CYP2C19   \n",
       "\n",
       "                                Drug(s)      PMID    Phenotype Category  \\\n",
       "0                            nifedipine  15634941  Other, Metabolism/PK   \n",
       "1                              warfarin  22248286                Dosage   \n",
       "2                              warfarin  33350885                Dosage   \n",
       "3                             efavirenz  16495778         Metabolism/PK   \n",
       "4  clomipramine, desmethyl clomipramine  28470111         Metabolism/PK   \n",
       "\n",
       "  Significance  \\\n",
       "0   not stated   \n",
       "1           no   \n",
       "2   not stated   \n",
       "3          yes   \n",
       "4           no   \n",
       "\n",
       "                                                                                                                                                                                                                                                                              Notes  \\\n",
       "0                                                                                                                                                                                        in vitro expression of the recombinant CYP3A4*17 allelic protein and the wild-type protein   \n",
       "1                                                                                                                                                                 No association was found between this variant and warfarin-maintenance dose. Described as CYP2A6*7 in this study.   \n",
       "2                                                                                                                                         \"This case suggests that CYP2C9 *11/*11 carriers require approximately two thirds less warfarin than CYP2C9\" normal function homozygotes.   \n",
       "3  Please note that in the paper the allele was referred to as CYP2B6*16. CYP2B6*16 and *18 alleles have been consolidated by PharmVar in Jan 2020, with *16 now listed as a suballele of *18 (CYP2B6*18.002). This annotation is updated to be on CYP2B6*18, instead of CYP2B6*16.   \n",
       "4                                                                                                                                                                                                                                                            in a single individual   \n",
       "\n",
       "                                                                                                                                                Sentence  \\\n",
       "0                                                             CYP3A4 *17 is associated with decreased metabolism of nifedipine as compared to CYP3A4 *1.   \n",
       "1  Allele G is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele A.   \n",
       "2                                                                                          CYP2C9 *11/*11 is associated with decreased dose of warfarin.   \n",
       "3                      CYP2B6 *1/*18 is associated with increased concentrations of efavirenz in people with HIV Infections as compared to CYP2B6 *1/*1.   \n",
       "4                                            CYP2C19 *1/*2 is associated with increased trough concentration of clomipramine and desmethyl clomipramine.   \n",
       "\n",
       "   Alleles Specialty Population Metabolizer types isPlural  \\\n",
       "0      *17                  NaN               NaN       Is   \n",
       "1        G                  NaN               NaN       Is   \n",
       "2  *11/*11                  NaN               NaN       Is   \n",
       "3   *1/*18                  NaN               NaN       Is   \n",
       "4    *1/*2                  NaN               NaN       Is   \n",
       "\n",
       "  Is/Is Not associated Direction of effect              PD/PK terms  \\\n",
       "0      Associated with           decreased            metabolism of   \n",
       "1  Not associated with           increased                  dose of   \n",
       "2      Associated with           decreased                  dose of   \n",
       "3      Associated with           increased        concentrations of   \n",
       "4      Associated with           increased  trough concentration of   \n",
       "\n",
       "  Multiple drugs And/or Population types  \\\n",
       "0                   NaN              NaN   \n",
       "1                   NaN   in people with   \n",
       "2                   NaN              NaN   \n",
       "3                   NaN   in people with   \n",
       "4                   and              NaN   \n",
       "\n",
       "                          Population Phenotypes or diseases  \\\n",
       "0                                                       NaN   \n",
       "1  Other:an international normalized ratio (INR) of 2.0-3.0   \n",
       "2                                                       NaN   \n",
       "3                                    Disease:HIV Infections   \n",
       "4                                                       NaN   \n",
       "\n",
       "  Multiple phenotypes or diseases And/or Comparison Allele(s) or Genotype(s)  \\\n",
       "0                                    NaN                                  *1   \n",
       "1                                    NaN                                   A   \n",
       "2                                    NaN                                 NaN   \n",
       "3                                    NaN                               *1/*1   \n",
       "4                                    NaN                                 NaN   \n",
       "\n",
       "  Comparison Metabolizer types  \n",
       "0                          NaN  \n",
       "1                          NaN  \n",
       "2                          NaN  \n",
       "3                          NaN  \n",
       "4                          NaN  "
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "var_drug_ann.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "12dada29-2a14-4992-acf4-45115aed57d2",
   "metadata": {
    "pycharm": {
     "name": "#%%\n"
    },
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Variant Annotation ID</th>\n",
       "      <th>Variant/Haplotypes</th>\n",
       "      <th>Gene</th>\n",
       "      <th>Drug(s)</th>\n",
       "      <th>PMID</th>\n",
       "      <th>Phenotype Category</th>\n",
       "      <th>Significance</th>\n",
       "      <th>Notes</th>\n",
       "      <th>Sentence</th>\n",
       "      <th>Alleles</th>\n",
       "      <th>Specialty Population</th>\n",
       "      <th>Assay type</th>\n",
       "      <th>Metabolizer types</th>\n",
       "      <th>isPlural</th>\n",
       "      <th>Is/Is Not associated</th>\n",
       "      <th>Direction of effect</th>\n",
       "      <th>Functional terms</th>\n",
       "      <th>Gene/gene product</th>\n",
       "      <th>When treated with/exposed to/when assayed with</th>\n",
       "      <th>Multiple drugs And/or</th>\n",
       "      <th>Cell type</th>\n",
       "      <th>Comparison Allele(s) or Genotype(s)</th>\n",
       "      <th>Comparison Metabolizer types</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1451148445</td>\n",
       "      <td>CYP2C19*1, CYP2C19*17</td>\n",
       "      <td>CYP2C19</td>\n",
       "      <td>normeperidine</td>\n",
       "      <td>30902024</td>\n",
       "      <td>NaN</td>\n",
       "      <td>not stated</td>\n",
       "      <td>In other in vitro experiments, normeperidine formation was significantly correlated with CYP2C19 activity, as measured by S-mephenytoin 4-hydroxylation.</td>\n",
       "      <td>CYP2C19 *17/*17 is associated with increased formation of normeperidine as compared to CYP2C19 *1/*1 + *1/*17.</td>\n",
       "      <td>*17/*17</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in human liver microsomes</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>increased</td>\n",
       "      <td>formation of</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>*1/*1 + *1/*17</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1447814273</td>\n",
       "      <td>rs9923231</td>\n",
       "      <td>VKORC1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>26847243</td>\n",
       "      <td>Other</td>\n",
       "      <td>no</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allele T is not associated with transcription of VKORC1 in HepG2 cells as compared to allele C.</td>\n",
       "      <td>T</td>\n",
       "      <td>NaN</td>\n",
       "      <td>luciferase assay</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Not associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>transcription of</td>\n",
       "      <td>VKORC1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in HepG2 cells</td>\n",
       "      <td>C</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1447814277</td>\n",
       "      <td>rs56314408</td>\n",
       "      <td>VKORC1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>26847243</td>\n",
       "      <td>Other</td>\n",
       "      <td>yes</td>\n",
       "      <td>In the European population, this SNPs is in high LD with rs9923231 but not other populations. This SNP disrupts a binding motif for transcription factor TFAP2A/C.</td>\n",
       "      <td>Allele C is associated with increased transcription of VKORC1 in HepG2 cells as compared to allele T.</td>\n",
       "      <td>C</td>\n",
       "      <td>NaN</td>\n",
       "      <td>luciferase assay</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>increased</td>\n",
       "      <td>transcription of</td>\n",
       "      <td>VKORC1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in HepG2 cells</td>\n",
       "      <td>T</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>1447990384</td>\n",
       "      <td>rs1065852</td>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>bufuralol</td>\n",
       "      <td>2211621</td>\n",
       "      <td>Metabolism/PK</td>\n",
       "      <td>not stated</td>\n",
       "      <td>In vitro experiments showed a significant decrease in CYP2D6 activity for the variant construct expressed in COS-1 cells as compared to wild-type.</td>\n",
       "      <td>Allele A is associated with decreased activity of CYP2D6 when assayed with bufuralol in COS-1 cells as compared to allele G.</td>\n",
       "      <td>A</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>decreased</td>\n",
       "      <td>activity of</td>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>when assayed with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in COS-1 cells</td>\n",
       "      <td>G</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>1448281185</td>\n",
       "      <td>CYP2B6*1, CYP2B6*6</td>\n",
       "      <td>CYP2B6</td>\n",
       "      <td>bupropion</td>\n",
       "      <td>27439448</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>The ratio of hydroxybupropion versus bupropion (AUC_hyd/ AUC_bup) in terms of area under the time-concentration curve (AUC) was used to assay CYP2B6 activity.</td>\n",
       "      <td>CYP2B6 *1/*1 is associated with increased activity of CYP2B6 when assayed with bupropion as compared to CYP2B6 *1/*6.</td>\n",
       "      <td>*1/*1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>increased</td>\n",
       "      <td>activity of</td>\n",
       "      <td>CYP2B6</td>\n",
       "      <td>when assayed with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>*1/*6</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  Variant Annotation ID     Variant/Haplotypes     Gene        Drug(s)  \\\n",
       "0            1451148445  CYP2C19*1, CYP2C19*17  CYP2C19  normeperidine   \n",
       "1            1447814273              rs9923231   VKORC1            NaN   \n",
       "2            1447814277             rs56314408   VKORC1            NaN   \n",
       "3            1447990384              rs1065852   CYP2D6      bufuralol   \n",
       "4            1448281185     CYP2B6*1, CYP2B6*6   CYP2B6      bupropion   \n",
       "\n",
       "       PMID Phenotype Category Significance  \\\n",
       "0  30902024                NaN   not stated   \n",
       "1  26847243              Other           no   \n",
       "2  26847243              Other          yes   \n",
       "3   2211621      Metabolism/PK   not stated   \n",
       "4  27439448           Efficacy          yes   \n",
       "\n",
       "                                                                                                                                                                Notes  \\\n",
       "0            In other in vitro experiments, normeperidine formation was significantly correlated with CYP2C19 activity, as measured by S-mephenytoin 4-hydroxylation.   \n",
       "1                                                                                                                                                                 NaN   \n",
       "2  In the European population, this SNPs is in high LD with rs9923231 but not other populations. This SNP disrupts a binding motif for transcription factor TFAP2A/C.   \n",
       "3                  In vitro experiments showed a significant decrease in CYP2D6 activity for the variant construct expressed in COS-1 cells as compared to wild-type.   \n",
       "4      The ratio of hydroxybupropion versus bupropion (AUC_hyd/ AUC_bup) in terms of area under the time-concentration curve (AUC) was used to assay CYP2B6 activity.   \n",
       "\n",
       "                                                                                                                       Sentence  \\\n",
       "0                CYP2C19 *17/*17 is associated with increased formation of normeperidine as compared to CYP2C19 *1/*1 + *1/*17.   \n",
       "1                               Allele T is not associated with transcription of VKORC1 in HepG2 cells as compared to allele C.   \n",
       "2                         Allele C is associated with increased transcription of VKORC1 in HepG2 cells as compared to allele T.   \n",
       "3  Allele A is associated with decreased activity of CYP2D6 when assayed with bufuralol in COS-1 cells as compared to allele G.   \n",
       "4         CYP2B6 *1/*1 is associated with increased activity of CYP2B6 when assayed with bupropion as compared to CYP2B6 *1/*6.   \n",
       "\n",
       "   Alleles Specialty Population                 Assay type Metabolizer types  \\\n",
       "0  *17/*17                  NaN  in human liver microsomes               NaN   \n",
       "1        T                  NaN           luciferase assay               NaN   \n",
       "2        C                  NaN           luciferase assay               NaN   \n",
       "3        A                  NaN                        NaN               NaN   \n",
       "4    *1/*1                  NaN                        NaN               NaN   \n",
       "\n",
       "  isPlural Is/Is Not associated Direction of effect  Functional terms  \\\n",
       "0       Is      Associated with           increased      formation of   \n",
       "1       Is  Not associated with                 NaN  transcription of   \n",
       "2       Is      Associated with           increased  transcription of   \n",
       "3       Is      Associated with           decreased       activity of   \n",
       "4       Is      Associated with           increased       activity of   \n",
       "\n",
       "  Gene/gene product When treated with/exposed to/when assayed with  \\\n",
       "0               NaN                                            NaN   \n",
       "1            VKORC1                                            NaN   \n",
       "2            VKORC1                                            NaN   \n",
       "3            CYP2D6                              when assayed with   \n",
       "4            CYP2B6                              when assayed with   \n",
       "\n",
       "  Multiple drugs And/or       Cell type Comparison Allele(s) or Genotype(s)  \\\n",
       "0                   NaN             NaN                      *1/*1 + *1/*17   \n",
       "1                   NaN  in HepG2 cells                                   C   \n",
       "2                   NaN  in HepG2 cells                                   T   \n",
       "3                   NaN  in COS-1 cells                                   G   \n",
       "4                   NaN             NaN                               *1/*6   \n",
       "\n",
       "  Comparison Metabolizer types  \n",
       "0                          NaN  \n",
       "1                          NaN  \n",
       "2                          NaN  \n",
       "3                          NaN  \n",
       "4                          NaN  "
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "var_fa_ann.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "70537798-e6fb-47f5-8ba2-6859c4b645a2",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Variant Annotation ID</th>\n",
       "      <th>Variant/Haplotypes</th>\n",
       "      <th>Gene</th>\n",
       "      <th>Drug(s)</th>\n",
       "      <th>PMID</th>\n",
       "      <th>Phenotype Category</th>\n",
       "      <th>Significance</th>\n",
       "      <th>Notes</th>\n",
       "      <th>Sentence</th>\n",
       "      <th>Alleles</th>\n",
       "      <th>Specialty Population</th>\n",
       "      <th>Metabolizer types</th>\n",
       "      <th>isPlural</th>\n",
       "      <th>Is/Is Not associated</th>\n",
       "      <th>Direction of effect</th>\n",
       "      <th>Side effect/efficacy/other</th>\n",
       "      <th>Phenotype</th>\n",
       "      <th>Multiple phenotypes And/or</th>\n",
       "      <th>When treated with/exposed to/when assayed with</th>\n",
       "      <th>Multiple drugs And/or</th>\n",
       "      <th>Population types</th>\n",
       "      <th>Population Phenotypes or diseases</th>\n",
       "      <th>Multiple phenotypes or diseases And/or</th>\n",
       "      <th>Comparison Allele(s) or Genotype(s)</th>\n",
       "      <th>Comparison Metabolizer types</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1449169911</td>\n",
       "      <td>HLA-B*35:08</td>\n",
       "      <td>HLA-B</td>\n",
       "      <td>lamotrigine</td>\n",
       "      <td>29238301</td>\n",
       "      <td>Toxicity</td>\n",
       "      <td>no</td>\n",
       "      <td>The allele was not significant when comparing allele frequency in cases of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (1/15) and controls (individuals without AEs who took lamotrigine) (0/50). The allele was significant when comparing between cases (1/15) and the general population (1/986).</td>\n",
       "      <td>HLA-B *35:08 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.</td>\n",
       "      <td>*35:08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Not associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>likelihood of</td>\n",
       "      <td>Side Effect:Maculopapular Exanthema, Side Effect:severe cutaneous adverse reactions, Side Effect:Stevens-Johnson Syndrome</td>\n",
       "      <td>or</td>\n",
       "      <td>when treated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Epilepsy</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>982022165</td>\n",
       "      <td>rs45607939</td>\n",
       "      <td>NAT2</td>\n",
       "      <td>sulfamethoxazole / trimethoprim</td>\n",
       "      <td>22850190</td>\n",
       "      <td>Toxicity</td>\n",
       "      <td>no</td>\n",
       "      <td>Minor allele frequencies were compared between cases (with drug-induced hypersensitivity) and controls.</td>\n",
       "      <td>Allele T is not associated with increased risk of Hypersensitivity when treated with sulfamethoxazole / trimethoprim in people with Infection.</td>\n",
       "      <td>T</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Not associated with</td>\n",
       "      <td>increased</td>\n",
       "      <td>risk of</td>\n",
       "      <td>Disease:Hypersensitivity</td>\n",
       "      <td>NaN</td>\n",
       "      <td>when treated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Infection</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>982022148</td>\n",
       "      <td>rs1799930</td>\n",
       "      <td>NAT2</td>\n",
       "      <td>sulfamethoxazole / trimethoprim</td>\n",
       "      <td>22850190</td>\n",
       "      <td>Toxicity</td>\n",
       "      <td>no</td>\n",
       "      <td>Minor allele frequencies were compared between cases (with drug-induced hypersensitivity) and controls.</td>\n",
       "      <td>Allele A is not associated with increased risk of Hypersensitivity when treated with sulfamethoxazole / trimethoprim in people with Infection.</td>\n",
       "      <td>A</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Not associated with</td>\n",
       "      <td>increased</td>\n",
       "      <td>risk of</td>\n",
       "      <td>Disease:Hypersensitivity</td>\n",
       "      <td>NaN</td>\n",
       "      <td>when treated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Infection</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>1451283480</td>\n",
       "      <td>rs16969968</td>\n",
       "      <td>CHRNA5</td>\n",
       "      <td>NaN</td>\n",
       "      <td>22071378</td>\n",
       "      <td>Other</td>\n",
       "      <td>yes</td>\n",
       "      <td>this was from meta-analysis of 27 studies but the number of total cases and the risk allele not clearly specified. Minor allele frequency was given for A allele.  Introduction states that variant is Asp398Asn, where Asn (A allele)  has lower nicotine response than Asp (G allele)  and may be at greater risk for nicotine addiction.</td>\n",
       "      <td>Allele A is associated with increased severity of Tobacco Use Disorder in people with Tobacco Use Disorder.</td>\n",
       "      <td>A</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>increased</td>\n",
       "      <td>severity of</td>\n",
       "      <td>Other:Tobacco Use Disorder</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Other:Tobacco Use Disorder</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>1444696916</td>\n",
       "      <td>rs267606617</td>\n",
       "      <td>MT-RNR1</td>\n",
       "      <td>streptomycin</td>\n",
       "      <td>7689389</td>\n",
       "      <td>Toxicity</td>\n",
       "      <td>not stated</td>\n",
       "      <td>Pedigree analysis with 3 separate families. Within the maternal lines, 15 individuals had the 1555G variant, took aminoglycoside antibiotics, and developed hearing loss. 100% of individuals with the 1555G variant who took aminoglycosides developed hearing loss. Homoplasmic. Please note that no statistical analyses were done.</td>\n",
       "      <td>Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.</td>\n",
       "      <td>G</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Side Effect:Ototoxicity</td>\n",
       "      <td>and</td>\n",
       "      <td>when treated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>A</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  Variant Annotation ID Variant/Haplotypes     Gene  \\\n",
       "0            1449169911        HLA-B*35:08    HLA-B   \n",
       "1             982022165         rs45607939     NAT2   \n",
       "2             982022148          rs1799930     NAT2   \n",
       "3            1451283480         rs16969968   CHRNA5   \n",
       "4            1444696916        rs267606617  MT-RNR1   \n",
       "\n",
       "                           Drug(s)      PMID Phenotype Category Significance  \\\n",
       "0                      lamotrigine  29238301           Toxicity           no   \n",
       "1  sulfamethoxazole / trimethoprim  22850190           Toxicity           no   \n",
       "2  sulfamethoxazole / trimethoprim  22850190           Toxicity           no   \n",
       "3                              NaN  22071378              Other          yes   \n",
       "4                     streptomycin   7689389           Toxicity   not stated   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                  Notes  \\\n",
       "0  The allele was not significant when comparing allele frequency in cases of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) and Maculopapular Exanthema (MPE) (1/15) and controls (individuals without AEs who took lamotrigine) (0/50). The allele was significant when comparing between cases (1/15) and the general population (1/986).   \n",
       "1                                                                                                                                                                                                                                                               Minor allele frequencies were compared between cases (with drug-induced hypersensitivity) and controls.   \n",
       "2                                                                                                                                                                                                                                                               Minor allele frequencies were compared between cases (with drug-induced hypersensitivity) and controls.   \n",
       "3                           this was from meta-analysis of 27 studies but the number of total cases and the risk allele not clearly specified. Minor allele frequency was given for A allele.  Introduction states that variant is Asp398Asn, where Asn (A allele)  has lower nicotine response than Asp (G allele)  and may be at greater risk for nicotine addiction.   \n",
       "4                                Pedigree analysis with 3 separate families. Within the maternal lines, 15 individuals had the 1555G variant, took aminoglycoside antibiotics, and developed hearing loss. 100% of individuals with the 1555G variant who took aminoglycosides developed hearing loss. Homoplasmic. Please note that no statistical analyses were done.   \n",
       "\n",
       "                                                                                                                                                                                           Sentence  \\\n",
       "0  HLA-B *35:08 is not associated with likelihood of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.   \n",
       "1                                                    Allele T is not associated with increased risk of Hypersensitivity when treated with sulfamethoxazole / trimethoprim in people with Infection.   \n",
       "2                                                    Allele A is not associated with increased risk of Hypersensitivity when treated with sulfamethoxazole / trimethoprim in people with Infection.   \n",
       "3                                                                                       Allele A is associated with increased severity of Tobacco Use Disorder in people with Tobacco Use Disorder.   \n",
       "4                                                                                                   Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.   \n",
       "\n",
       "  Alleles Specialty Population Metabolizer types isPlural  \\\n",
       "0  *35:08                  NaN               NaN       Is   \n",
       "1       T                  NaN               NaN       Is   \n",
       "2       A                  NaN               NaN       Is   \n",
       "3       A                  NaN               NaN       Is   \n",
       "4       G                  NaN               NaN       Is   \n",
       "\n",
       "  Is/Is Not associated Direction of effect Side effect/efficacy/other  \\\n",
       "0  Not associated with                 NaN              likelihood of   \n",
       "1  Not associated with           increased                    risk of   \n",
       "2  Not associated with           increased                    risk of   \n",
       "3      Associated with           increased                severity of   \n",
       "4      Associated with                 NaN                        NaN   \n",
       "\n",
       "                                                                                                                   Phenotype  \\\n",
       "0  Side Effect:Maculopapular Exanthema, Side Effect:severe cutaneous adverse reactions, Side Effect:Stevens-Johnson Syndrome   \n",
       "1                                                                                                   Disease:Hypersensitivity   \n",
       "2                                                                                                   Disease:Hypersensitivity   \n",
       "3                                                                                                 Other:Tobacco Use Disorder   \n",
       "4                                                                                                    Side Effect:Ototoxicity   \n",
       "\n",
       "  Multiple phenotypes And/or When treated with/exposed to/when assayed with  \\\n",
       "0                         or                              when treated with   \n",
       "1                        NaN                              when treated with   \n",
       "2                        NaN                              when treated with   \n",
       "3                        NaN                                            NaN   \n",
       "4                        and                              when treated with   \n",
       "\n",
       "  Multiple drugs And/or Population types Population Phenotypes or diseases  \\\n",
       "0                   NaN   in people with                  Disease:Epilepsy   \n",
       "1                   NaN   in people with                 Disease:Infection   \n",
       "2                   NaN   in people with                 Disease:Infection   \n",
       "3                   NaN   in people with        Other:Tobacco Use Disorder   \n",
       "4                   NaN              NaN                               NaN   \n",
       "\n",
       "  Multiple phenotypes or diseases And/or Comparison Allele(s) or Genotype(s)  \\\n",
       "0                                    NaN                                 NaN   \n",
       "1                                    NaN                                 NaN   \n",
       "2                                    NaN                                 NaN   \n",
       "3                                    NaN                                 NaN   \n",
       "4                                    NaN                                   A   \n",
       "\n",
       "  Comparison Metabolizer types  \n",
       "0                          NaN  \n",
       "1                          NaN  \n",
       "2                          NaN  \n",
       "3                          NaN  \n",
       "4                          NaN  "
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "var_pheno_ann.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3b84a02e-1791-4a6b-8223-d904442ddf7c",
   "metadata": {},
   "source": [
    "The 3 annotations tables provide evidence for the clinical annotations, can be connected by joining with the `clinical_ann_evidence.tsv` file. In general a clinical annotation can have multiple variant annotations as evidence, and a variant annotation can be used as evidence for multiple clinical annotations.\n",
    "\n",
    "Each of these tables has a \"Direction of effect\" column, and the type of \"effect\" is different for each - likelihood of side effects, formation of product, metabolism of drug, etc.\n",
    "\n",
    "**Question for OT**: when we say \"direction of effect\", do we mean any of these \"effects\"? I.e. should we include all three of these tables or focus on one?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "d43fd147-43b4-4541-9595-f757da937e60",
   "metadata": {},
   "outputs": [],
   "source": [
    "clinical_annotations = read_tsv_to_df(os.path.join(data_dir, 'clinical_annotations.tsv'))\n",
    "clinical_ann_evidence = read_tsv_to_df(os.path.join(data_dir, 'clinical_ann_evidence.tsv'))\n",
    "clinical_ann_alleles = read_tsv_to_df(os.path.join(data_dir, 'clinical_ann_alleles.tsv'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "id": "1a553aac-a9f7-4579-ab7c-05fa6f90ddfe",
   "metadata": {},
   "outputs": [],
   "source": [
    "main_df = pd.merge(clinical_annotations, clinical_ann_evidence, how='left', on=ID_COL_NAME)\n",
    "# main_df = pd.merge(main_df, clinical_ann_alleles, on=ID_COL_NAME)\n",
    "main_df = main_df[[\n",
    "    # Main table\n",
    "    'Clinical Annotation ID', 'Variant/Haplotypes', 'Gene', 'Level of Evidence', 'Phenotype Category', 'Drug(s)', 'Phenotype(s)',\n",
    "    # Evidence table\n",
    "    'Evidence ID', 'Evidence Type', 'PMID', 'Summary',\n",
    "]]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 123,
   "id": "5b691865-956d-4543-97fc-798be58842bd",
   "metadata": {},
   "outputs": [],
   "source": [
    "# https://www.pharmgkb.org/clinicalAnnotation/981755803 - has all three types of variant annotation evidence, plus label/guideline evidence\n",
    "df_981755803 = main_df[main_df[ID_COL_NAME] == '981755803']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "id": "f5bb8c9e-baeb-4ef6-9373-7c38a333601c",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Just look at one clinical annotation as an example\n",
    "df_981755803_drug = pd.merge(df_981755803, var_drug_ann, left_on='Evidence ID', right_on='Variant Annotation ID', how='inner', suffixes=(None, '_var_drug'))\n",
    "df_981755803_pheno = pd.merge(df_981755803, var_pheno_ann, left_on='Evidence ID', right_on='Variant Annotation ID', how='inner', suffixes=(None, '_var_pheno'))\n",
    "df_981755803_fa = pd.merge(df_981755803, var_fa_ann, left_on='Evidence ID', right_on='Variant Annotation ID', how='inner', suffixes=(None, '_var_fa'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 125,
   "id": "811adf62-6f79-4451-9a3e-2772057e4a01",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "30"
      ]
     },
     "execution_count": 125,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df_981755803)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 126,
   "id": "61affced-e597-490f-8580-f77ca577aec7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "24"
      ]
     },
     "execution_count": 126,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df_981755803_drug)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "id": "4ec0a5bd-8661-45a2-9370-a2522ed2150e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2"
      ]
     },
     "execution_count": 127,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df_981755803_fa)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "id": "923be524-0d8d-46d6-bb31-10a0f504905d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2"
      ]
     },
     "execution_count": 128,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df_981755803_pheno)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "id": "c4a15bc6-90fc-4d4b-bd0e-621b8ffd6093",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Clinical Annotation ID</th>\n",
       "      <th>Variant/Haplotypes</th>\n",
       "      <th>Gene</th>\n",
       "      <th>Level of Evidence</th>\n",
       "      <th>Phenotype Category</th>\n",
       "      <th>Drug(s)</th>\n",
       "      <th>Phenotype(s)</th>\n",
       "      <th>Evidence ID</th>\n",
       "      <th>Evidence Type</th>\n",
       "      <th>PMID</th>\n",
       "      <th>Summary</th>\n",
       "      <th>Variant Annotation ID</th>\n",
       "      <th>Variant/Haplotypes_var_drug</th>\n",
       "      <th>Gene_var_drug</th>\n",
       "      <th>Drug(s)_var_drug</th>\n",
       "      <th>PMID_var_drug</th>\n",
       "      <th>Phenotype Category_var_drug</th>\n",
       "      <th>Significance</th>\n",
       "      <th>Notes</th>\n",
       "      <th>Sentence</th>\n",
       "      <th>Alleles</th>\n",
       "      <th>Specialty Population</th>\n",
       "      <th>Metabolizer types</th>\n",
       "      <th>isPlural</th>\n",
       "      <th>Is/Is Not associated</th>\n",
       "      <th>Direction of effect</th>\n",
       "      <th>PD/PK terms</th>\n",
       "      <th>Multiple drugs And/or</th>\n",
       "      <th>Population types</th>\n",
       "      <th>Population Phenotypes or diseases</th>\n",
       "      <th>Multiple phenotypes or diseases And/or</th>\n",
       "      <th>Comparison Allele(s) or Genotype(s)</th>\n",
       "      <th>Comparison Metabolizer types</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>981755665</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>21083385</td>\n",
       "      <td>Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>981755665</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>21083385</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>not stated</td>\n",
       "      <td>Clinical trials were carried out to test efficacy of ivacaftor selecting only patients with the CFTR G551D mutation on at least one allele (genotype AA or AG).</td>\n",
       "      <td>Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>AA + AG</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Are</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>981755678</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>22047557</td>\n",
       "      <td>Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>981755678</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>22047557</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>not stated</td>\n",
       "      <td>A clinical trial that selected patients with the G551D CFTR mutation (rs75527207 genotype AA or AG). Patients without this mutation were excluded. One patient included in the placebo group was homozygous for F508del (rs113993960 genotype del/del).</td>\n",
       "      <td>Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>AA + AG</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Are</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>982009991</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>23590265</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.</td>\n",
       "      <td>982009991</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>23590265</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>Patients aged 6-11 at time of screening who had at least one allele with the G551D mutation (allele A at position rs75527207) were recruited for this trial. Ivacaftor is only indicated in CF patients with this mutation. Significant improvements in lung function were seen in the ivacaftor treatment group compared to placebo.</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>Pediatric</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in children with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1183629335</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>24066763</td>\n",
       "      <td>Genotype AA is associated with response to ivacaftor in women with Cystic Fibrosis.</td>\n",
       "      <td>1183629335</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>24066763</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>not stated</td>\n",
       "      <td>Case report of a female homozygous for the G551D CFTR mutation (genotype AA) in which ivacaftor was efficacious: increased absolute change in percent of predicted FEV1, increased weight and walk distance and decreased sweat chloride levels over a 12 month course with no sign of plateau to date.</td>\n",
       "      <td>Genotype AA is associated with response to ivacaftor in women with Cystic Fibrosis.</td>\n",
       "      <td>AA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in women with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1448423752</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>27773592</td>\n",
       "      <td>Genotypes AA + AG is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.</td>\n",
       "      <td>1448423752</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>27773592</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>The outcome of change in sweat chloride was correlated with change in FEV1 in patients with cystic fibrosis and found to have improved results for both.</td>\n",
       "      <td>Genotypes AA + AG is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.</td>\n",
       "      <td>AA + AG</td>\n",
       "      <td>Pediatric</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>increased</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1449191908</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>25682022</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>1449191908</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>25682022</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>not stated</td>\n",
       "      <td>Study was an expanded access program targeted at patients with severe lung disease and was not powered to determine efficacy. Majority of patients reported an improvement in FEV following 24 weeks of treatment.</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>Pediatric</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1449192055</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>28711222</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>1449192055</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>28711222</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>G551D allele. Statistically significant increases in FEV1, weight and BMI and statistically significant decreases in sweat chloride level, the number of days of antibiotic treatment and in the use of some maintenance treatments.; No differences in bone density, pancreatic insufficiency and cystic fibrosis related diabetes were observed.</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>Pediatric</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1449192093</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>25311995</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>1449192093</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>25311995</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>not stated</td>\n",
       "      <td>G551 D allele. Increases in FEV1, body weight, CFQ-R scores and time to first pulmonary exacerbation were observed.</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>Pediatric</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1449192439</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>28611235</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>1449192439</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>28611235</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>G551D allele. FEV1, Alfred wellness score, exercise time, CFQ-R score and sweat chloride levels showed a significant improvement following ivacaftor treatment as compared to placebo while other outcomes (VO2, ventilation, cardiac response nd recovery following exercise) did not.</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1449192481</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>26135562</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>1449192481</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>26135562</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>G551D allele. Analysis of CFQ-R scores from participants in the STRIVE trial. Scores for eating problems, health perceptions, physical functioning, respiratory symptoms, social functioning, treatment burden and vitality showed significant improvements following ivacaftor treatment.</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>Pediatric</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1449192494</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>25171465</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.</td>\n",
       "      <td>1449192494</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>25171465</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>not stated</td>\n",
       "      <td>Case study of a pediatric cystic fibrosis patient. Improvements in sweat chloride, BMI,  bronchiectasis and lung function reported following ivacaftor treatment.</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>Pediatric</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in children with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1449192576</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>25755212</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>1449192576</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>25755212</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>Post hoc analysis of clinical outcomes of the STRIVE and ENVISION trials. Participants were split into tertiles based on FEV1 score and outcomes in change in baseline FEV1, body weight, CFQ-R score and sweat chloride levels as well as number of days of pulmonary exacerbation were assessed. All outcomes were significantly improved in the upper tertile, all outcomes apart from number of days of pulmonary exacerbation were significantly improved in the middle tertile and absolute change in FEV1, body weight and sweat chloride levels were significantly improved in the lower tertile.</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>Pediatric</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1449192615</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>26568242</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>1449192615</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>26568242</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>Response measured by changes in sweat chloride levels, FEV1 and BMI.</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>Pediatric</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1449192709</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>25473543</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>1449192709</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>25473543</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>not stated</td>\n",
       "      <td>G551D allele. Case report of three patients with the F508del/G551D genotype. Reported improvements in FEV1, body weight, sweat chloride levels and scores in the respiratory domain of the CFQ-R.</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1449192721</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>25145599</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>1449192721</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>25145599</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>G551D allele. Significant increases in %FVC and %FEV1 compared to baseline were seen at 6 months of ivacaftor treatment, but both measures declined to baseline by 12 months of ivacaftor treatment. Significant improvements in BMI, body weight, sinus disease status and sweat chloride levels were seen at 12 months of ivacaftor treatment.</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>Pediatric</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1450043422</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>23628510</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.</td>\n",
       "      <td>1450043422</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>23628510</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>Pediatric</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in children with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1184512440</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>25049054</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>1184512440</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>25049054</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>Patients with at least one G551D-CFTR allele were recruited and treated with ivacaftor for one year. Mean weight and BMI improved at 6 months from baseline, but only mean weight was increased again at 12 months.  Mean percentage FVC, FEV1 and FEF25-75% returned to baseline levels by 12 months of treatment.</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>981755746</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>22942289</td>\n",
       "      <td>Allele A is associated with increased response to ivacaftor.</td>\n",
       "      <td>981755746</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>22942289</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>not stated</td>\n",
       "      <td>In vitro studies using proteoliposomes containing CFTR, or CFTR with the G551D mutation (rs75527207 allele A), or CFTR with the F508del mutation (rs113993960 allele del). Ivacaftor in the presence of ATP potentiated channel activity of CFTR-G551D.</td>\n",
       "      <td>Allele A is associated with increased response to ivacaftor.</td>\n",
       "      <td>A</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>increased</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>981755699</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>19846789</td>\n",
       "      <td>Allele A is associated with increased response to ivacaftor.</td>\n",
       "      <td>981755699</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>19846789</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>In vitro assays that show ivacaftor potentiates CFTR with the G551D mutation (rs75527207 allele A) - see details described in study parameters.</td>\n",
       "      <td>Allele A is associated with increased response to ivacaftor.</td>\n",
       "      <td>A</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>increased</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>981755787</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>22293084</td>\n",
       "      <td>Allele A is associated with increased response to ivacaftor.</td>\n",
       "      <td>981755787</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>22293084</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>as compared to baseline. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Before treatment, cells were activated by exposure to PKA and ATP before ivacaftor treatment. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Cells expressing G551D-CFTR (rs75527207 allele A) responded to ivacaftor treatment with a significantly enhanced channel open probability and increased chloride transport. Single channel current amplitude at 80mV was not significantly enhanced.</td>\n",
       "      <td>Allele A is associated with increased response to ivacaftor.</td>\n",
       "      <td>A</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>increased</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1043737597</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>23757359</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>1043737597</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>23757359</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>A retrospective study of patients in Germany with severe Cystic Fibrosis (FEV1 &lt;40%predicted) with the G551D mutation who were treated with ivacaftor. On average, FEV1and body weight  increased significantly, though response was variable in this patient group and several patients discontinued ivacaftor for different complications.</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>982006840</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>23313410</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in men with Cystic Fibrosis.</td>\n",
       "      <td>982006840</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>23313410</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>not stated</td>\n",
       "      <td>A case report of lung function improvements 6 months after treatment with ivacaftor in a male patient with severe lung disease - he had the CFTR G511D (rsrs75527207 allele A)/deltaF508 genotype (rs113993960 del CTT) and so could be given ivacaftor.</td>\n",
       "      <td>Allele A is associated with response to ivacaftor in men with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in men with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1446903789</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>24461666</td>\n",
       "      <td>Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>1446903789</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>24461666</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>The authors wanted to assess the efficacy of ivacaftor in patients with cystic fibrosis who have normal spirometry. The authors assessed lung function improvement in patients using lung clearance index (LCI) as well as forced expiratory volume in 1 second (FEV1), and only included patients with &lt; 90% FEV1 values. The primary outcome was change in LCI from baseline. This was a phase 2, multi-centre, placebo-controlled, 2x2 crossover study. One group, sequence 1, took placebo first, followed by 28 day washout, then took ivacaftor 150 mg 2x daily for 4 weeks. The second group had the sequence of treatment reversed.</td>\n",
       "      <td>Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>AA + AG</td>\n",
       "      <td>Pediatric</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Are</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1448099051</td>\n",
       "      <td>Variant Drug Annotation</td>\n",
       "      <td>27158673</td>\n",
       "      <td>Genotypes AA + AG are associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.</td>\n",
       "      <td>1448099051</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>27158673</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>Measured in adult patients, with changes in lung volume, sweat chloride, distensibility, wall thickness, expiratory lumen area, and inspiratory lumen area measured before starting ivacaftor and 48 hour after starting ivacaftor.</td>\n",
       "      <td>Genotypes AA + AG are associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.</td>\n",
       "      <td>AA + AG</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Are</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>increased</td>\n",
       "      <td>response to</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Clinical Annotation ID Variant/Haplotypes  Gene Level of Evidence  \\\n",
       "0               981755803         rs75527207  CFTR                1A   \n",
       "1               981755803         rs75527207  CFTR                1A   \n",
       "2               981755803         rs75527207  CFTR                1A   \n",
       "3               981755803         rs75527207  CFTR                1A   \n",
       "4               981755803         rs75527207  CFTR                1A   \n",
       "5               981755803         rs75527207  CFTR                1A   \n",
       "6               981755803         rs75527207  CFTR                1A   \n",
       "7               981755803         rs75527207  CFTR                1A   \n",
       "8               981755803         rs75527207  CFTR                1A   \n",
       "9               981755803         rs75527207  CFTR                1A   \n",
       "10              981755803         rs75527207  CFTR                1A   \n",
       "11              981755803         rs75527207  CFTR                1A   \n",
       "12              981755803         rs75527207  CFTR                1A   \n",
       "13              981755803         rs75527207  CFTR                1A   \n",
       "14              981755803         rs75527207  CFTR                1A   \n",
       "15              981755803         rs75527207  CFTR                1A   \n",
       "16              981755803         rs75527207  CFTR                1A   \n",
       "17              981755803         rs75527207  CFTR                1A   \n",
       "18              981755803         rs75527207  CFTR                1A   \n",
       "19              981755803         rs75527207  CFTR                1A   \n",
       "20              981755803         rs75527207  CFTR                1A   \n",
       "21              981755803         rs75527207  CFTR                1A   \n",
       "22              981755803         rs75527207  CFTR                1A   \n",
       "23              981755803         rs75527207  CFTR                1A   \n",
       "\n",
       "   Phenotype Category    Drug(s)     Phenotype(s) Evidence ID  \\\n",
       "0            Efficacy  ivacaftor  Cystic Fibrosis   981755665   \n",
       "1            Efficacy  ivacaftor  Cystic Fibrosis   981755678   \n",
       "2            Efficacy  ivacaftor  Cystic Fibrosis   982009991   \n",
       "3            Efficacy  ivacaftor  Cystic Fibrosis  1183629335   \n",
       "4            Efficacy  ivacaftor  Cystic Fibrosis  1448423752   \n",
       "5            Efficacy  ivacaftor  Cystic Fibrosis  1449191908   \n",
       "6            Efficacy  ivacaftor  Cystic Fibrosis  1449192055   \n",
       "7            Efficacy  ivacaftor  Cystic Fibrosis  1449192093   \n",
       "8            Efficacy  ivacaftor  Cystic Fibrosis  1449192439   \n",
       "9            Efficacy  ivacaftor  Cystic Fibrosis  1449192481   \n",
       "10           Efficacy  ivacaftor  Cystic Fibrosis  1449192494   \n",
       "11           Efficacy  ivacaftor  Cystic Fibrosis  1449192576   \n",
       "12           Efficacy  ivacaftor  Cystic Fibrosis  1449192615   \n",
       "13           Efficacy  ivacaftor  Cystic Fibrosis  1449192709   \n",
       "14           Efficacy  ivacaftor  Cystic Fibrosis  1449192721   \n",
       "15           Efficacy  ivacaftor  Cystic Fibrosis  1450043422   \n",
       "16           Efficacy  ivacaftor  Cystic Fibrosis  1184512440   \n",
       "17           Efficacy  ivacaftor  Cystic Fibrosis   981755746   \n",
       "18           Efficacy  ivacaftor  Cystic Fibrosis   981755699   \n",
       "19           Efficacy  ivacaftor  Cystic Fibrosis   981755787   \n",
       "20           Efficacy  ivacaftor  Cystic Fibrosis  1043737597   \n",
       "21           Efficacy  ivacaftor  Cystic Fibrosis   982006840   \n",
       "22           Efficacy  ivacaftor  Cystic Fibrosis  1446903789   \n",
       "23           Efficacy  ivacaftor  Cystic Fibrosis  1448099051   \n",
       "\n",
       "              Evidence Type      PMID  \\\n",
       "0   Variant Drug Annotation  21083385   \n",
       "1   Variant Drug Annotation  22047557   \n",
       "2   Variant Drug Annotation  23590265   \n",
       "3   Variant Drug Annotation  24066763   \n",
       "4   Variant Drug Annotation  27773592   \n",
       "5   Variant Drug Annotation  25682022   \n",
       "6   Variant Drug Annotation  28711222   \n",
       "7   Variant Drug Annotation  25311995   \n",
       "8   Variant Drug Annotation  28611235   \n",
       "9   Variant Drug Annotation  26135562   \n",
       "10  Variant Drug Annotation  25171465   \n",
       "11  Variant Drug Annotation  25755212   \n",
       "12  Variant Drug Annotation  26568242   \n",
       "13  Variant Drug Annotation  25473543   \n",
       "14  Variant Drug Annotation  25145599   \n",
       "15  Variant Drug Annotation  23628510   \n",
       "16  Variant Drug Annotation  25049054   \n",
       "17  Variant Drug Annotation  22942289   \n",
       "18  Variant Drug Annotation  19846789   \n",
       "19  Variant Drug Annotation  22293084   \n",
       "20  Variant Drug Annotation  23757359   \n",
       "21  Variant Drug Annotation  23313410   \n",
       "22  Variant Drug Annotation  24461666   \n",
       "23  Variant Drug Annotation  27158673   \n",
       "\n",
       "                                                                                                                             Summary  \\\n",
       "0                                        Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "1                                        Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "2                                                Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.   \n",
       "3                                                Genotype AA is associated with response to ivacaftor in women with Cystic Fibrosis.   \n",
       "4    Genotypes AA + AG is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.   \n",
       "5                                                  Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "6                                                  Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "7                                                  Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "8                                                  Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "9                                                  Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "10                                               Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.   \n",
       "11                                                 Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "12                                                 Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "13                                                 Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "14                                                 Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "15                                               Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.   \n",
       "16                                                 Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "17                                                                      Allele A is associated with increased response to ivacaftor.   \n",
       "18                                                                      Allele A is associated with increased response to ivacaftor.   \n",
       "19                                                                      Allele A is associated with increased response to ivacaftor.   \n",
       "20                                                 Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "21                                                    Allele A is associated with response to ivacaftor in men with Cystic Fibrosis.   \n",
       "22                                       Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "23  Genotypes AA + AG are associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.   \n",
       "\n",
       "   Variant Annotation ID Variant/Haplotypes_var_drug Gene_var_drug  \\\n",
       "0              981755665                  rs75527207          CFTR   \n",
       "1              981755678                  rs75527207          CFTR   \n",
       "2              982009991                  rs75527207          CFTR   \n",
       "3             1183629335                  rs75527207          CFTR   \n",
       "4             1448423752                  rs75527207          CFTR   \n",
       "5             1449191908                  rs75527207          CFTR   \n",
       "6             1449192055                  rs75527207          CFTR   \n",
       "7             1449192093                  rs75527207          CFTR   \n",
       "8             1449192439                  rs75527207          CFTR   \n",
       "9             1449192481                  rs75527207          CFTR   \n",
       "10            1449192494                  rs75527207          CFTR   \n",
       "11            1449192576                  rs75527207          CFTR   \n",
       "12            1449192615                  rs75527207          CFTR   \n",
       "13            1449192709                  rs75527207          CFTR   \n",
       "14            1449192721                  rs75527207          CFTR   \n",
       "15            1450043422                  rs75527207          CFTR   \n",
       "16            1184512440                  rs75527207          CFTR   \n",
       "17             981755746                  rs75527207          CFTR   \n",
       "18             981755699                  rs75527207          CFTR   \n",
       "19             981755787                  rs75527207          CFTR   \n",
       "20            1043737597                  rs75527207          CFTR   \n",
       "21             982006840                  rs75527207          CFTR   \n",
       "22            1446903789                  rs75527207          CFTR   \n",
       "23            1448099051                  rs75527207          CFTR   \n",
       "\n",
       "   Drug(s)_var_drug PMID_var_drug Phenotype Category_var_drug Significance  \\\n",
       "0         ivacaftor      21083385                    Efficacy   not stated   \n",
       "1         ivacaftor      22047557                    Efficacy   not stated   \n",
       "2         ivacaftor      23590265                    Efficacy          yes   \n",
       "3         ivacaftor      24066763                    Efficacy   not stated   \n",
       "4         ivacaftor      27773592                    Efficacy          yes   \n",
       "5         ivacaftor      25682022                    Efficacy   not stated   \n",
       "6         ivacaftor      28711222                    Efficacy          yes   \n",
       "7         ivacaftor      25311995                    Efficacy   not stated   \n",
       "8         ivacaftor      28611235                    Efficacy          yes   \n",
       "9         ivacaftor      26135562                    Efficacy          yes   \n",
       "10        ivacaftor      25171465                    Efficacy   not stated   \n",
       "11        ivacaftor      25755212                    Efficacy          yes   \n",
       "12        ivacaftor      26568242                    Efficacy          yes   \n",
       "13        ivacaftor      25473543                    Efficacy   not stated   \n",
       "14        ivacaftor      25145599                    Efficacy          yes   \n",
       "15        ivacaftor      23628510                    Efficacy          yes   \n",
       "16        ivacaftor      25049054                    Efficacy          yes   \n",
       "17        ivacaftor      22942289                    Efficacy   not stated   \n",
       "18        ivacaftor      19846789                    Efficacy          yes   \n",
       "19        ivacaftor      22293084                    Efficacy          yes   \n",
       "20        ivacaftor      23757359                    Efficacy          yes   \n",
       "21        ivacaftor      23313410                    Efficacy   not stated   \n",
       "22        ivacaftor      24461666                    Efficacy          yes   \n",
       "23        ivacaftor      27158673                    Efficacy          yes   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Notes  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Clinical trials were carried out to test efficacy of ivacaftor selecting only patients with the CFTR G551D mutation on at least one allele (genotype AA or AG).   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                       A clinical trial that selected patients with the G551D CFTR mutation (rs75527207 genotype AA or AG). Patients without this mutation were excluded. One patient included in the placebo group was homozygous for F508del (rs113993960 genotype del/del).   \n",
       "2                                                                                                                                                                                                                                                                                                         Patients aged 6-11 at time of screening who had at least one allele with the G551D mutation (allele A at position rs75527207) were recruited for this trial. Ivacaftor is only indicated in CF patients with this mutation. Significant improvements in lung function were seen in the ivacaftor treatment group compared to placebo.   \n",
       "3                                                                                                                                                                                                                                                                                                                                       Case report of a female homozygous for the G551D CFTR mutation (genotype AA) in which ivacaftor was efficacious: increased absolute change in percent of predicted FEV1, increased weight and walk distance and decreased sweat chloride levels over a 12 month course with no sign of plateau to date.   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      The outcome of change in sweat chloride was correlated with change in FEV1 in patients with cystic fibrosis and found to have improved results for both.   \n",
       "5                                                                                                                                                                                                                                                                                                                                                                                                                            Study was an expanded access program targeted at patients with severe lung disease and was not powered to determine efficacy. Majority of patients reported an improvement in FEV following 24 weeks of treatment.   \n",
       "6                                                                                                                                                                                                                                                                                            G551D allele. Statistically significant increases in FEV1, weight and BMI and statistically significant decreases in sweat chloride level, the number of days of antibiotic treatment and in the use of some maintenance treatments.; No differences in bone density, pancreatic insufficiency and cystic fibrosis related diabetes were observed.   \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           G551 D allele. Increases in FEV1, body weight, CFQ-R scores and time to first pulmonary exacerbation were observed.   \n",
       "8                                                                                                                                                                                                                                                                                                                                                       G551D allele. FEV1, Alfred wellness score, exercise time, CFQ-R score and sweat chloride levels showed a significant improvement following ivacaftor treatment as compared to placebo while other outcomes (VO2, ventilation, cardiac response nd recovery following exercise) did not.   \n",
       "9                                                                                                                                                                                                                                                                                                                                                    G551D allele. Analysis of CFQ-R scores from participants in the STRIVE trial. Scores for eating problems, health perceptions, physical functioning, respiratory symptoms, social functioning, treatment burden and vitality showed significant improvements following ivacaftor treatment.   \n",
       "10                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Case study of a pediatric cystic fibrosis patient. Improvements in sweat chloride, BMI,  bronchiectasis and lung function reported following ivacaftor treatment.   \n",
       "11                                    Post hoc analysis of clinical outcomes of the STRIVE and ENVISION trials. Participants were split into tertiles based on FEV1 score and outcomes in change in baseline FEV1, body weight, CFQ-R score and sweat chloride levels as well as number of days of pulmonary exacerbation were assessed. All outcomes were significantly improved in the upper tertile, all outcomes apart from number of days of pulmonary exacerbation were significantly improved in the middle tertile and absolute change in FEV1, body weight and sweat chloride levels were significantly improved in the lower tertile.   \n",
       "12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Response measured by changes in sweat chloride levels, FEV1 and BMI.   \n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                                                            G551D allele. Case report of three patients with the F508del/G551D genotype. Reported improvements in FEV1, body weight, sweat chloride levels and scores in the respiratory domain of the CFQ-R.   \n",
       "14                                                                                                                                                                                                                                                                                             G551D allele. Significant increases in %FVC and %FEV1 compared to baseline were seen at 6 months of ivacaftor treatment, but both measures declined to baseline by 12 months of ivacaftor treatment. Significant improvements in BMI, body weight, sinus disease status and sweat chloride levels were seen at 12 months of ivacaftor treatment.   \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NaN   \n",
       "16                                                                                                                                                                                                                                                                                                                          Patients with at least one G551D-CFTR allele were recruited and treated with ivacaftor for one year. Mean weight and BMI improved at 6 months from baseline, but only mean weight was increased again at 12 months.  Mean percentage FVC, FEV1 and FEF25-75% returned to baseline levels by 12 months of treatment.   \n",
       "17                                                                                                                                                                                                                                                                                                                                                                                      In vitro studies using proteoliposomes containing CFTR, or CFTR with the G551D mutation (rs75527207 allele A), or CFTR with the F508del mutation (rs113993960 allele del). Ivacaftor in the presence of ATP potentiated channel activity of CFTR-G551D.   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              In vitro assays that show ivacaftor potentiates CFTR with the G551D mutation (rs75527207 allele A) - see details described in study parameters.   \n",
       "19                                                                                                          as compared to baseline. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Before treatment, cells were activated by exposure to PKA and ATP before ivacaftor treatment. In vitro assays using transfected Fisher Rat Thyroid cells expressing CFTR. Cells expressing G551D-CFTR (rs75527207 allele A) responded to ivacaftor treatment with a significantly enhanced channel open probability and increased chloride transport. Single channel current amplitude at 80mV was not significantly enhanced.   \n",
       "20                                                                                                                                                                                                                                                                                                 A retrospective study of patients in Germany with severe Cystic Fibrosis (FEV1 <40%predicted) with the G551D mutation who were treated with ivacaftor. On average, FEV1and body weight  increased significantly, though response was variable in this patient group and several patients discontinued ivacaftor for different complications.   \n",
       "21                                                                                                                                                                                                                                                                                                                                                                                     A case report of lung function improvements 6 months after treatment with ivacaftor in a male patient with severe lung disease - he had the CFTR G511D (rsrs75527207 allele A)/deltaF508 genotype (rs113993960 del CTT) and so could be given ivacaftor.   \n",
       "22  The authors wanted to assess the efficacy of ivacaftor in patients with cystic fibrosis who have normal spirometry. The authors assessed lung function improvement in patients using lung clearance index (LCI) as well as forced expiratory volume in 1 second (FEV1), and only included patients with < 90% FEV1 values. The primary outcome was change in LCI from baseline. This was a phase 2, multi-centre, placebo-controlled, 2x2 crossover study. One group, sequence 1, took placebo first, followed by 28 day washout, then took ivacaftor 150 mg 2x daily for 4 weeks. The second group had the sequence of treatment reversed.   \n",
       "23                                                                                                                                                                                                                                                                                                                                                                                                          Measured in adult patients, with changes in lung volume, sweat chloride, distensibility, wall thickness, expiratory lumen area, and inspiratory lumen area measured before starting ivacaftor and 48 hour after starting ivacaftor.   \n",
       "\n",
       "                                                                                                                            Sentence  \\\n",
       "0                                        Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "1                                        Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "2                                                Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.   \n",
       "3                                                Genotype AA is associated with response to ivacaftor in women with Cystic Fibrosis.   \n",
       "4    Genotypes AA + AG is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.   \n",
       "5                                                  Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "6                                                  Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "7                                                  Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "8                                                  Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "9                                                  Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "10                                               Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.   \n",
       "11                                                 Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "12                                                 Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "13                                                 Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "14                                                 Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "15                                               Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.   \n",
       "16                                                 Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "17                                                                      Allele A is associated with increased response to ivacaftor.   \n",
       "18                                                                      Allele A is associated with increased response to ivacaftor.   \n",
       "19                                                                      Allele A is associated with increased response to ivacaftor.   \n",
       "20                                                 Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "21                                                    Allele A is associated with response to ivacaftor in men with Cystic Fibrosis.   \n",
       "22                                       Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.   \n",
       "23  Genotypes AA + AG are associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.   \n",
       "\n",
       "    Alleles Specialty Population Metabolizer types isPlural  \\\n",
       "0   AA + AG                  NaN               NaN      Are   \n",
       "1   AA + AG                  NaN               NaN      Are   \n",
       "2         A            Pediatric               NaN       Is   \n",
       "3        AA                  NaN               NaN       Is   \n",
       "4   AA + AG            Pediatric               NaN       Is   \n",
       "5         A            Pediatric               NaN       Is   \n",
       "6         A            Pediatric               NaN       Is   \n",
       "7         A            Pediatric               NaN       Is   \n",
       "8         A                  NaN               NaN       Is   \n",
       "9         A            Pediatric               NaN       Is   \n",
       "10        A            Pediatric               NaN       Is   \n",
       "11        A            Pediatric               NaN       Is   \n",
       "12        A            Pediatric               NaN       Is   \n",
       "13        A                  NaN               NaN       Is   \n",
       "14        A            Pediatric               NaN       Is   \n",
       "15        A            Pediatric               NaN       Is   \n",
       "16        A                  NaN               NaN       Is   \n",
       "17        A                  NaN               NaN       Is   \n",
       "18        A                  NaN               NaN       Is   \n",
       "19        A                  NaN               NaN       Is   \n",
       "20        A                  NaN               NaN       Is   \n",
       "21        A                  NaN               NaN       Is   \n",
       "22  AA + AG            Pediatric               NaN      Are   \n",
       "23  AA + AG                  NaN               NaN      Are   \n",
       "\n",
       "   Is/Is Not associated Direction of effect  PD/PK terms  \\\n",
       "0       Associated with                 NaN  response to   \n",
       "1       Associated with                 NaN  response to   \n",
       "2       Associated with                 NaN  response to   \n",
       "3       Associated with                 NaN  response to   \n",
       "4       Associated with           increased  response to   \n",
       "5       Associated with                 NaN  response to   \n",
       "6       Associated with                 NaN  response to   \n",
       "7       Associated with                 NaN  response to   \n",
       "8       Associated with                 NaN  response to   \n",
       "9       Associated with                 NaN  response to   \n",
       "10      Associated with                 NaN  response to   \n",
       "11      Associated with                 NaN  response to   \n",
       "12      Associated with                 NaN  response to   \n",
       "13      Associated with                 NaN  response to   \n",
       "14      Associated with                 NaN  response to   \n",
       "15      Associated with                 NaN  response to   \n",
       "16      Associated with                 NaN  response to   \n",
       "17      Associated with           increased  response to   \n",
       "18      Associated with           increased  response to   \n",
       "19      Associated with           increased  response to   \n",
       "20      Associated with                 NaN  response to   \n",
       "21      Associated with                 NaN  response to   \n",
       "22      Associated with                 NaN  response to   \n",
       "23      Associated with           increased  response to   \n",
       "\n",
       "   Multiple drugs And/or  Population types Population Phenotypes or diseases  \\\n",
       "0                    NaN    in people with           Disease:Cystic Fibrosis   \n",
       "1                    NaN    in people with           Disease:Cystic Fibrosis   \n",
       "2                    NaN  in children with           Disease:Cystic Fibrosis   \n",
       "3                    NaN     in women with           Disease:Cystic Fibrosis   \n",
       "4                    NaN    in people with           Disease:Cystic Fibrosis   \n",
       "5                    NaN    in people with           Disease:Cystic Fibrosis   \n",
       "6                    NaN    in people with           Disease:Cystic Fibrosis   \n",
       "7                    NaN    in people with           Disease:Cystic Fibrosis   \n",
       "8                    NaN    in people with           Disease:Cystic Fibrosis   \n",
       "9                    NaN    in people with           Disease:Cystic Fibrosis   \n",
       "10                   NaN  in children with           Disease:Cystic Fibrosis   \n",
       "11                   NaN    in people with           Disease:Cystic Fibrosis   \n",
       "12                   NaN    in people with           Disease:Cystic Fibrosis   \n",
       "13                   NaN    in people with           Disease:Cystic Fibrosis   \n",
       "14                   NaN    in people with           Disease:Cystic Fibrosis   \n",
       "15                   NaN  in children with           Disease:Cystic Fibrosis   \n",
       "16                   NaN    in people with           Disease:Cystic Fibrosis   \n",
       "17                   NaN               NaN                               NaN   \n",
       "18                   NaN               NaN                               NaN   \n",
       "19                   NaN               NaN                               NaN   \n",
       "20                   NaN    in people with           Disease:Cystic Fibrosis   \n",
       "21                   NaN       in men with           Disease:Cystic Fibrosis   \n",
       "22                   NaN    in people with           Disease:Cystic Fibrosis   \n",
       "23                   NaN    in people with           Disease:Cystic Fibrosis   \n",
       "\n",
       "   Multiple phenotypes or diseases And/or Comparison Allele(s) or Genotype(s)  \\\n",
       "0                                     NaN                                 NaN   \n",
       "1                                     NaN                                 NaN   \n",
       "2                                     NaN                                 NaN   \n",
       "3                                     NaN                                 NaN   \n",
       "4                                     NaN                                  GG   \n",
       "5                                     NaN                                 NaN   \n",
       "6                                     NaN                                 NaN   \n",
       "7                                     NaN                                 NaN   \n",
       "8                                     NaN                                 NaN   \n",
       "9                                     NaN                                 NaN   \n",
       "10                                    NaN                                 NaN   \n",
       "11                                    NaN                                 NaN   \n",
       "12                                    NaN                                 NaN   \n",
       "13                                    NaN                                 NaN   \n",
       "14                                    NaN                                 NaN   \n",
       "15                                    NaN                                 NaN   \n",
       "16                                    NaN                                 NaN   \n",
       "17                                    NaN                                 NaN   \n",
       "18                                    NaN                                 NaN   \n",
       "19                                    NaN                                 NaN   \n",
       "20                                    NaN                                 NaN   \n",
       "21                                    NaN                                 NaN   \n",
       "22                                    NaN                                 NaN   \n",
       "23                                    NaN                                  GG   \n",
       "\n",
       "   Comparison Metabolizer types  \n",
       "0                           NaN  \n",
       "1                           NaN  \n",
       "2                           NaN  \n",
       "3                           NaN  \n",
       "4                           NaN  \n",
       "5                           NaN  \n",
       "6                           NaN  \n",
       "7                           NaN  \n",
       "8                           NaN  \n",
       "9                           NaN  \n",
       "10                          NaN  \n",
       "11                          NaN  \n",
       "12                          NaN  \n",
       "13                          NaN  \n",
       "14                          NaN  \n",
       "15                          NaN  \n",
       "16                          NaN  \n",
       "17                          NaN  \n",
       "18                          NaN  \n",
       "19                          NaN  \n",
       "20                          NaN  \n",
       "21                          NaN  \n",
       "22                          NaN  \n",
       "23                          NaN  "
      ]
     },
     "execution_count": 85,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_981755803_drug"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 138,
   "id": "86225d03-93ea-4d22-8569-0bb1360f4d66",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Clinical Annotation ID</th>\n",
       "      <th>Variant/Haplotypes</th>\n",
       "      <th>Gene</th>\n",
       "      <th>Level of Evidence</th>\n",
       "      <th>Phenotype Category</th>\n",
       "      <th>Drug(s)</th>\n",
       "      <th>Phenotype(s)</th>\n",
       "      <th>Evidence ID</th>\n",
       "      <th>Evidence Type</th>\n",
       "      <th>PMID</th>\n",
       "      <th>Summary</th>\n",
       "      <th>Variant Annotation ID</th>\n",
       "      <th>Variant/Haplotypes_var_fa</th>\n",
       "      <th>Gene_var_fa</th>\n",
       "      <th>Drug(s)_var_fa</th>\n",
       "      <th>PMID_var_fa</th>\n",
       "      <th>Phenotype Category_var_fa</th>\n",
       "      <th>Significance</th>\n",
       "      <th>Notes</th>\n",
       "      <th>Sentence</th>\n",
       "      <th>Alleles</th>\n",
       "      <th>Specialty Population</th>\n",
       "      <th>Assay type</th>\n",
       "      <th>Metabolizer types</th>\n",
       "      <th>isPlural</th>\n",
       "      <th>Is/Is Not associated</th>\n",
       "      <th>Direction of effect</th>\n",
       "      <th>Functional terms</th>\n",
       "      <th>Gene/gene product</th>\n",
       "      <th>When treated with/exposed to/when assayed with</th>\n",
       "      <th>Multiple drugs And/or</th>\n",
       "      <th>Cell type</th>\n",
       "      <th>Comparison Allele(s) or Genotype(s)</th>\n",
       "      <th>Comparison Metabolizer types</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1043737620</td>\n",
       "      <td>Variant Functional Assay Annotation</td>\n",
       "      <td>23757361</td>\n",
       "      <td>Allele A is associated with increased activity of CFTR when treated with ivacaftor in transfected CHO cells.</td>\n",
       "      <td>1043737620</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>23757361</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>compared to no treatment. Ivacaftor stimulated CFTR activity in CFTR-G551D expressing CHO cells (as measured by iodine efflux).</td>\n",
       "      <td>Allele A is associated with increased activity of CFTR when treated with ivacaftor in transfected CHO cells.</td>\n",
       "      <td>A</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>increased</td>\n",
       "      <td>activity of</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>when treated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in transfected CHO cells</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1043737636</td>\n",
       "      <td>Variant Functional Assay Annotation</td>\n",
       "      <td>23891399</td>\n",
       "      <td>Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.</td>\n",
       "      <td>1043737636</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>23891399</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>G551D allele. 55.3 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).</td>\n",
       "      <td>Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.</td>\n",
       "      <td>A</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>activity of</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>when treated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in FRT cell lines</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  Clinical Annotation ID Variant/Haplotypes  Gene Level of Evidence  \\\n",
       "0              981755803         rs75527207  CFTR                1A   \n",
       "1              981755803         rs75527207  CFTR                1A   \n",
       "\n",
       "  Phenotype Category    Drug(s)     Phenotype(s) Evidence ID  \\\n",
       "0           Efficacy  ivacaftor  Cystic Fibrosis  1043737620   \n",
       "1           Efficacy  ivacaftor  Cystic Fibrosis  1043737636   \n",
       "\n",
       "                         Evidence Type      PMID  \\\n",
       "0  Variant Functional Assay Annotation  23757361   \n",
       "1  Variant Functional Assay Annotation  23891399   \n",
       "\n",
       "                                                                                                        Summary  \\\n",
       "0  Allele A is associated with increased activity of CFTR when treated with ivacaftor in transfected CHO cells.   \n",
       "1                   Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.   \n",
       "\n",
       "  Variant Annotation ID Variant/Haplotypes_var_fa Gene_var_fa Drug(s)_var_fa  \\\n",
       "0            1043737620                rs75527207        CFTR      ivacaftor   \n",
       "1            1043737636                rs75527207        CFTR      ivacaftor   \n",
       "\n",
       "  PMID_var_fa Phenotype Category_var_fa Significance  \\\n",
       "0    23757361                  Efficacy          yes   \n",
       "1    23891399                  Efficacy          yes   \n",
       "\n",
       "                                                                                                                               Notes  \\\n",
       "0    compared to no treatment. Ivacaftor stimulated CFTR activity in CFTR-G551D expressing CHO cells (as measured by iodine efflux).   \n",
       "1  G551D allele. 55.3 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).   \n",
       "\n",
       "                                                                                                       Sentence  \\\n",
       "0  Allele A is associated with increased activity of CFTR when treated with ivacaftor in transfected CHO cells.   \n",
       "1                   Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.   \n",
       "\n",
       "  Alleles Specialty Population Assay type Metabolizer types isPlural  \\\n",
       "0       A                  NaN        NaN               NaN       Is   \n",
       "1       A                  NaN        NaN               NaN       Is   \n",
       "\n",
       "  Is/Is Not associated Direction of effect Functional terms Gene/gene product  \\\n",
       "0      Associated with           increased      activity of              CFTR   \n",
       "1      Associated with                 NaN      activity of              CFTR   \n",
       "\n",
       "  When treated with/exposed to/when assayed with Multiple drugs And/or  \\\n",
       "0                              when treated with                   NaN   \n",
       "1                              when treated with                   NaN   \n",
       "\n",
       "                  Cell type Comparison Allele(s) or Genotype(s)  \\\n",
       "0  in transfected CHO cells                                 NaN   \n",
       "1         in FRT cell lines                                 NaN   \n",
       "\n",
       "  Comparison Metabolizer types  \n",
       "0                          NaN  \n",
       "1                          NaN  "
      ]
     },
     "execution_count": 138,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_981755803_fa"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "id": "49c52d4d-8c99-4788-a922-310ac566b4f6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Clinical Annotation ID</th>\n",
       "      <th>Variant/Haplotypes</th>\n",
       "      <th>Gene</th>\n",
       "      <th>Level of Evidence</th>\n",
       "      <th>Phenotype Category</th>\n",
       "      <th>Drug(s)</th>\n",
       "      <th>Phenotype(s)</th>\n",
       "      <th>Evidence ID</th>\n",
       "      <th>Evidence Type</th>\n",
       "      <th>PMID</th>\n",
       "      <th>Summary</th>\n",
       "      <th>Variant Annotation ID</th>\n",
       "      <th>Variant/Haplotypes_var_pheno</th>\n",
       "      <th>Gene_var_pheno</th>\n",
       "      <th>Drug(s)_var_pheno</th>\n",
       "      <th>PMID_var_pheno</th>\n",
       "      <th>Phenotype Category_var_pheno</th>\n",
       "      <th>Significance</th>\n",
       "      <th>Notes</th>\n",
       "      <th>Sentence</th>\n",
       "      <th>Alleles</th>\n",
       "      <th>Specialty Population</th>\n",
       "      <th>Metabolizer types</th>\n",
       "      <th>isPlural</th>\n",
       "      <th>Is/Is Not associated</th>\n",
       "      <th>Direction of effect</th>\n",
       "      <th>Side effect/efficacy/other</th>\n",
       "      <th>Phenotype</th>\n",
       "      <th>Multiple phenotypes And/or</th>\n",
       "      <th>When treated with/exposed to/when assayed with</th>\n",
       "      <th>Multiple drugs And/or</th>\n",
       "      <th>Population types</th>\n",
       "      <th>Population Phenotypes or diseases</th>\n",
       "      <th>Multiple phenotypes or diseases And/or</th>\n",
       "      <th>Comparison Allele(s) or Genotype(s)</th>\n",
       "      <th>Comparison Metabolizer types</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1448267532</td>\n",
       "      <td>Variant Phenotype Annotation</td>\n",
       "      <td>27745802</td>\n",
       "      <td>Genotypes AA + AG is associated with decreased severity of bone density when treated with ivacaftor in people with Cystic Fibrosis as compared to genotype GG.</td>\n",
       "      <td>1448267532</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>27745802</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>Bone mineral density compared before and after 1 year of treatment with ivacaftor using dual energy X-ray absorptiometry at the L2-L4 lumbar spine. All patients were pancreatic insufficient.</td>\n",
       "      <td>Genotypes AA + AG is associated with decreased severity of bone density when treated with ivacaftor in people with Cystic Fibrosis as compared to genotype GG.</td>\n",
       "      <td>AA + AG</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>decreased</td>\n",
       "      <td>severity of</td>\n",
       "      <td>Side Effect:bone density</td>\n",
       "      <td>and</td>\n",
       "      <td>when treated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GG</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>981755803</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>1A</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>1449192031</td>\n",
       "      <td>Variant Phenotype Annotation</td>\n",
       "      <td>28651844</td>\n",
       "      <td>Allele A is associated with decreased likelihood of cystic fibrosis pulmonary exacerbation when treated with ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>1449192031</td>\n",
       "      <td>rs75527207</td>\n",
       "      <td>CFTR</td>\n",
       "      <td>ivacaftor</td>\n",
       "      <td>28651844</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>yes</td>\n",
       "      <td>G551D allele. Patients receiving ivacaftor treatment had a reduced rate of pulmonary exacerbation events compared to patients receiving a placebo.</td>\n",
       "      <td>Allele A is associated with decreased likelihood of cystic fibrosis pulmonary exacerbation when treated with ivacaftor in people with Cystic Fibrosis.</td>\n",
       "      <td>A</td>\n",
       "      <td>Pediatric</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Is</td>\n",
       "      <td>Associated with</td>\n",
       "      <td>decreased</td>\n",
       "      <td>likelihood of</td>\n",
       "      <td>Disease:cystic fibrosis pulmonary exacerbation</td>\n",
       "      <td>and</td>\n",
       "      <td>when treated with</td>\n",
       "      <td>NaN</td>\n",
       "      <td>in people with</td>\n",
       "      <td>Disease:Cystic Fibrosis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  Clinical Annotation ID Variant/Haplotypes  Gene Level of Evidence  \\\n",
       "0              981755803         rs75527207  CFTR                1A   \n",
       "1              981755803         rs75527207  CFTR                1A   \n",
       "\n",
       "  Phenotype Category    Drug(s)     Phenotype(s) Evidence ID  \\\n",
       "0           Efficacy  ivacaftor  Cystic Fibrosis  1448267532   \n",
       "1           Efficacy  ivacaftor  Cystic Fibrosis  1449192031   \n",
       "\n",
       "                  Evidence Type      PMID  \\\n",
       "0  Variant Phenotype Annotation  27745802   \n",
       "1  Variant Phenotype Annotation  28651844   \n",
       "\n",
       "                                                                                                                                                          Summary  \\\n",
       "0  Genotypes AA + AG is associated with decreased severity of bone density when treated with ivacaftor in people with Cystic Fibrosis as compared to genotype GG.   \n",
       "1          Allele A is associated with decreased likelihood of cystic fibrosis pulmonary exacerbation when treated with ivacaftor in people with Cystic Fibrosis.   \n",
       "\n",
       "  Variant Annotation ID Variant/Haplotypes_var_pheno Gene_var_pheno  \\\n",
       "0            1448267532                   rs75527207           CFTR   \n",
       "1            1449192031                   rs75527207           CFTR   \n",
       "\n",
       "  Drug(s)_var_pheno PMID_var_pheno Phenotype Category_var_pheno Significance  \\\n",
       "0         ivacaftor       27745802                     Efficacy          yes   \n",
       "1         ivacaftor       28651844                     Efficacy          yes   \n",
       "\n",
       "                                                                                                                                                                                            Notes  \\\n",
       "0  Bone mineral density compared before and after 1 year of treatment with ivacaftor using dual energy X-ray absorptiometry at the L2-L4 lumbar spine. All patients were pancreatic insufficient.   \n",
       "1                                              G551D allele. Patients receiving ivacaftor treatment had a reduced rate of pulmonary exacerbation events compared to patients receiving a placebo.   \n",
       "\n",
       "                                                                                                                                                         Sentence  \\\n",
       "0  Genotypes AA + AG is associated with decreased severity of bone density when treated with ivacaftor in people with Cystic Fibrosis as compared to genotype GG.   \n",
       "1          Allele A is associated with decreased likelihood of cystic fibrosis pulmonary exacerbation when treated with ivacaftor in people with Cystic Fibrosis.   \n",
       "\n",
       "   Alleles Specialty Population Metabolizer types isPlural  \\\n",
       "0  AA + AG                  NaN               NaN       Is   \n",
       "1        A            Pediatric               NaN       Is   \n",
       "\n",
       "  Is/Is Not associated Direction of effect Side effect/efficacy/other  \\\n",
       "0      Associated with           decreased                severity of   \n",
       "1      Associated with           decreased              likelihood of   \n",
       "\n",
       "                                        Phenotype Multiple phenotypes And/or  \\\n",
       "0                        Side Effect:bone density                        and   \n",
       "1  Disease:cystic fibrosis pulmonary exacerbation                        and   \n",
       "\n",
       "  When treated with/exposed to/when assayed with Multiple drugs And/or  \\\n",
       "0                              when treated with                   NaN   \n",
       "1                              when treated with                   NaN   \n",
       "\n",
       "  Population types Population Phenotypes or diseases  \\\n",
       "0   in people with           Disease:Cystic Fibrosis   \n",
       "1   in people with           Disease:Cystic Fibrosis   \n",
       "\n",
       "  Multiple phenotypes or diseases And/or Comparison Allele(s) or Genotype(s)  \\\n",
       "0                                    NaN                                  GG   \n",
       "1                                    NaN                                 NaN   \n",
       "\n",
       "  Comparison Metabolizer types  \n",
       "0                          NaN  \n",
       "1                          NaN  "
      ]
     },
     "execution_count": 94,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_981755803_pheno"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "id": "08abfc16-b970-4f45-96c1-5e1584ba9a0e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "28"
      ]
     },
     "execution_count": 93,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Comparing number of PMIDs vs. number of evidence\n",
    "len(set(df_981755803_drug['PMID']) | set(df_981755803_pheno['PMID']) | set(df_981755803_fa['PMID']))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e5d40be8-65a0-487b-a175-d98aa502aaeb",
   "metadata": {},
   "source": [
    "### Observations so far\n",
    "Clinical annotation [981755803](https://www.pharmgkb.org/clinicalAnnotation/981755803) has 30 supporting evidence:\n",
    "* 24 variant/drug annotations\n",
    "* 2 variant/functional assay annotations\n",
    "* 2 variant/phenotype annotations\n",
    "* 2 others (drug labels & guidelines, present in another data download so not included here)\n",
    "\n",
    "Each variant annotation is associated with a PMID, these are 1:1.\n",
    "* We should think about whether we want to preserve the PMID & evidence associations.\n",
    "\n",
    "These annotations seem much more specific than the clinical annotations, e.g.\n",
    "* they distinguish between \"disease\" and \"side effect\" (check how often)\n",
    "* if there are multiple phenotypes or drugs, they specify whether these should be \"and\"s or \"or\"s\n",
    "\n",
    "These annotations are specific to one or more alleles or genotypes, so we will need to associate them accordingly.\n",
    "* Annoyingly multiples are represented in yet another way, e.g. `AA + AG` (check how consistent this is)\n",
    "\n",
    "It would good if we could select the relevant columns from the 3 variant annotation tables and merge them into a unified representation, so we don't have to manage them separately in the pipelines or in the UI\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "85e68502-9717-40bd-989a-e9aa7376879d",
   "metadata": {},
   "source": [
    "## 2. Coverage and data consistency"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "id": "57d1856b-6b82-4084-9def-5c95db9cdfef",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "5111"
      ]
     },
     "execution_count": 97,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(clinical_annotations)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "id": "23b76684-1ceb-4dd5-b95a-931a57fbcafc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "15129"
      ]
     },
     "execution_count": 129,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Exploded on evidence - average 3 per annotation\n",
    "len(main_df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 130,
   "id": "8d92bd51-114f-4b9f-961e-3afcc9084560",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Add all the var annotation tables - this will be a huge mess\n",
    "main_with_var = pd.merge(main_df, var_drug_ann, left_on='Evidence ID', right_on='Variant Annotation ID', how='left', suffixes=(None, '_var_drug'))\n",
    "main_with_var = pd.merge(main_with_var, var_pheno_ann, left_on='Evidence ID', right_on='Variant Annotation ID', how='left', suffixes=(None, '_var_pheno'))\n",
    "main_with_var = pd.merge(main_with_var, var_fa_ann, left_on='Evidence ID', right_on='Variant Annotation ID', how='left', suffixes=(None, '_var_fa'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "id": "d45aa8c2-a6d5-4caf-bebc-8ccf40e4fcc3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "15129"
      ]
     },
     "execution_count": 131,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# sanity check\n",
    "len(main_with_var)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 144,
   "id": "67228cc8-68e9-4265-997d-047a31458c7d",
   "metadata": {},
   "outputs": [],
   "source": [
    "ca_with_var_evidence = set(main_with_var[main_with_var['Sentence'].notna() | main_with_var['Sentence_var_pheno'].notna() | main_with_var['Sentence_var_fa'].notna()][ID_COL_NAME])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 147,
   "id": "84438d2c-21c2-4411-bbda-742a2f3e94da",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "5111"
      ]
     },
     "execution_count": 147,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Every clinical annotation has at least one variant annotation as supporting evidence\n",
    "len(ca_with_var_evidence)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 148,
   "id": "a9814220-d767-4e1e-b3ca-ea27b61a5777",
   "metadata": {},
   "outputs": [],
   "source": [
    "ca_with_doe_evidence = set(main_with_var[main_with_var['Direction of effect'].notna() | main_with_var['Direction of effect_var_pheno'].notna() | main_with_var['Direction of effect_var_fa'].notna()][ID_COL_NAME])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 149,
   "id": "3be7753e-902e-47ec-985e-e2b08f70158d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "4917"
      ]
     },
     "execution_count": 149,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Most contain some kind of direction of effect info\n",
    "len(ca_with_doe_evidence)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "98c401bc-d920-405f-90a1-93016c7ed9ae",
   "metadata": {},
   "source": [
    "Observations so far:\n",
    "* Every clinical annotation has at least one variant annotation as supporting evidence\n",
    "* Most contain some kind of direction of effect info (i.e. in one of the three tables)\n",
    "   * => coverage is good, assuming we care about all three types of effects"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 132,
   "id": "01ff8ed9-bdc2-454e-9a68-c9530b9f5de8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['Clinical Annotation ID', 'Variant/Haplotypes', 'Gene',\n",
       "       'Level of Evidence', 'Phenotype Category', 'Drug(s)', 'Phenotype(s)',\n",
       "       'Evidence ID', 'Evidence Type', 'PMID', 'Summary',\n",
       "       'Variant Annotation ID', 'Variant/Haplotypes_var_drug', 'Gene_var_drug',\n",
       "       'Drug(s)_var_drug', 'PMID_var_drug', 'Phenotype Category_var_drug',\n",
       "       'Significance', 'Notes', 'Sentence', 'Alleles', 'Specialty Population',\n",
       "       'Metabolizer types', 'isPlural', 'Is/Is Not associated',\n",
       "       'Direction of effect', 'PD/PK terms', 'Multiple drugs And/or',\n",
       "       'Population types', 'Population Phenotypes or diseases',\n",
       "       'Multiple phenotypes or diseases And/or',\n",
       "       'Comparison Allele(s) or Genotype(s)', 'Comparison Metabolizer types',\n",
       "       'Variant Annotation ID_var_pheno', 'Variant/Haplotypes_var_pheno',\n",
       "       'Gene_var_pheno', 'Drug(s)_var_pheno', 'PMID_var_pheno',\n",
       "       'Phenotype Category_var_pheno', 'Significance_var_pheno',\n",
       "       'Notes_var_pheno', 'Sentence_var_pheno', 'Alleles_var_pheno',\n",
       "       'Specialty Population_var_pheno', 'Metabolizer types_var_pheno',\n",
       "       'isPlural_var_pheno', 'Is/Is Not associated_var_pheno',\n",
       "       'Direction of effect_var_pheno', 'Side effect/efficacy/other',\n",
       "       'Phenotype', 'Multiple phenotypes And/or',\n",
       "       'When treated with/exposed to/when assayed with',\n",
       "       'Multiple drugs And/or_var_pheno', 'Population types_var_pheno',\n",
       "       'Population Phenotypes or diseases_var_pheno',\n",
       "       'Multiple phenotypes or diseases And/or_var_pheno',\n",
       "       'Comparison Allele(s) or Genotype(s)_var_pheno',\n",
       "       'Comparison Metabolizer types_var_pheno',\n",
       "       'Variant Annotation ID_var_fa', 'Variant/Haplotypes_var_fa',\n",
       "       'Gene_var_fa', 'Drug(s)_var_fa', 'PMID_var_fa',\n",
       "       'Phenotype Category_var_fa', 'Significance_var_fa', 'Notes_var_fa',\n",
       "       'Sentence_var_fa', 'Alleles_var_fa', 'Specialty Population_var_fa',\n",
       "       'Assay type', 'Metabolizer types_var_fa', 'isPlural_var_fa',\n",
       "       'Is/Is Not associated_var_fa', 'Direction of effect_var_fa',\n",
       "       'Functional terms', 'Gene/gene product',\n",
       "       'When treated with/exposed to/when assayed with_var_fa',\n",
       "       'Multiple drugs And/or_var_fa', 'Cell type',\n",
       "       'Comparison Allele(s) or Genotype(s)_var_fa',\n",
       "       'Comparison Metabolizer types_var_fa'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 132,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "main_with_var.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 133,
   "id": "126d1762-ae36-4003-989d-c28d96b78e12",
   "metadata": {},
   "outputs": [],
   "source": [
    "all_var_ann_cols = set(var_drug_ann.columns) | set(var_fa_ann.columns) | set(var_pheno_ann.columns)\n",
    "common_var_ann_cols = set(var_drug_ann.columns) & set(var_fa_ann.columns) & set(var_pheno_ann.columns)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 134,
   "id": "86c927dd-2dfc-4957-9afb-50eb7334d213",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Alleles',\n",
       " 'Comparison Allele(s) or Genotype(s)',\n",
       " 'Comparison Metabolizer types',\n",
       " 'Direction of effect',\n",
       " 'Drug(s)',\n",
       " 'Gene',\n",
       " 'Is/Is Not associated',\n",
       " 'Metabolizer types',\n",
       " 'Multiple drugs And/or',\n",
       " 'Notes',\n",
       " 'PMID',\n",
       " 'Phenotype Category',\n",
       " 'Sentence',\n",
       " 'Significance',\n",
       " 'Specialty Population',\n",
       " 'Variant Annotation ID',\n",
       " 'Variant/Haplotypes',\n",
       " 'isPlural'}"
      ]
     },
     "execution_count": 134,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "common_var_ann_cols"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 135,
   "id": "44b41088-2162-4138-a719-1de7e4c3c156",
   "metadata": {},
   "outputs": [],
   "source": [
    "unique_var_ann_cols = all_var_ann_cols - common_var_ann_cols"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "id": "4f19f44b-d472-4b1b-ae13-1faa8a3ea5b9",
   "metadata": {},
   "outputs": [],
   "source": [
    "# annotate with origin table\n",
    "annotated_unique_var_ann_cols = {'drug':[], 'fa':[], 'pheno':[]}\n",
    "for c in unique_var_ann_cols:\n",
    "    if c in var_drug_ann.columns:\n",
    "        annotated_unique_var_ann_cols['drug'].append(c)\n",
    "    if c in var_fa_ann.columns:\n",
    "        annotated_unique_var_ann_cols['fa'].append(c)\n",
    "    if c in var_pheno_ann.columns:\n",
    "        annotated_unique_var_ann_cols['pheno'].append(c)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 137,
   "id": "888398bc-00ce-45bd-af1b-0053c47ba3c3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'drug': ['Multiple phenotypes or diseases And/or',\n",
       "  'Population types',\n",
       "  'Population Phenotypes or diseases',\n",
       "  'PD/PK terms'],\n",
       " 'fa': ['Cell type',\n",
       "  'Functional terms',\n",
       "  'When treated with/exposed to/when assayed with',\n",
       "  'Gene/gene product',\n",
       "  'Assay type'],\n",
       " 'pheno': ['Multiple phenotypes or diseases And/or',\n",
       "  'Side effect/efficacy/other',\n",
       "  'Multiple phenotypes And/or',\n",
       "  'When treated with/exposed to/when assayed with',\n",
       "  'Population types',\n",
       "  'Population Phenotypes or diseases',\n",
       "  'Phenotype']}"
      ]
     },
     "execution_count": 137,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "annotated_unique_var_ann_cols"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0a3b9cbd-c13e-4e98-831a-aa508fc69d10",
   "metadata": {},
   "source": [
    "* Population phenotype always goes with \"multiple phenotypes and/or\" (note functional assay doesn't mention phenotype - I guess there's no multiples in the gene product?)\n",
    "    * where does the main table phenotype come from?? OT is overwriting this now but I'm still confused\n",
    "* Drug (main table) always goes with \"multiple drugs and/or\"\n",
    "* Comparison alleles in theory I guess tells us something about the reference or baseline, doesn't seem frequently filled in though\n",
    "\n",
    "Sentence examples:\n",
    "* **drug**: \"Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.\"\n",
    "    * alleles = \"AA + AG\"\n",
    "    * direction of effect = [none]\n",
    "    * pd/pk term = \"response to\"\n",
    "    * drug = \"ivacaftor\"\n",
    "    * population types = \"people\"\n",
    "    * population phenotype = \"cystic fibrosis\"\n",
    "* **fa**: \"Allele A is associated with increased activity of CFTR when treated with ivacaftor in transfected CHO cells.\"\n",
    "    * alleles = \"A\"\n",
    "    * direction of effect = \"increased\"\n",
    "    * functional term = \"activity of\"\n",
    "    * gene/gene product = \"CFTR\"\n",
    "    * when treated with/exposed to/assayed with = \"when treated with\"\n",
    "    * drug = \"ivacaftor\"\n",
    "    * cell type = \"transfected CHO cells\"\n",
    "* **pheno**: \"Genotypes AA + AG is associated with decreased severity of bone density when treated with ivacaftor in people with Cystic Fibrosis as compared to genotype GG.\"\n",
    "    * alleles = \"AA + AG\"\n",
    "    * direction of effect = \"decreased\"\n",
    "    * side effect/efficacy/other = \"severity of\"\n",
    "    * phenotype = \"bone density\" **< note distinction between this and population phenotype**\n",
    "    * when treated with/exposed to/assayed with = \"when treated with\"\n",
    "    * drug = \"ivacaftor\"\n",
    "    * population types = \"people\"\n",
    "    * population phenotype = \"cystic fibrosis\"\n",
    "\n",
    "For the simplest direction of effect annotation (i.e. not including the population, cell type, etc.), I think we only strictly need the following:\n",
    "1. direction of effect\n",
    "2. pd/pk term | functional term | side effect/efficacy/other\n",
    "3. drug | gene/gene product | phenotype\n",
    "\n",
    "This tells us the direction (1) and what the effect is (2&3).\n",
    "Of course we also need the alleles to associate with the appropriate evidence string, and the \"is/is not associated\" column so we don't report negative results (unless we want to)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 161,
   "id": "d5a77ac2-d058-426b-8d54-10aefd5023c3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'decreased', 'increased', nan}"
      ]
     },
     "execution_count": 161,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Check some vocab\n",
    "set(main_with_var['Direction of effect']) | set(main_with_var['Direction of effect_var_pheno']) | set(main_with_var['Direction of effect_var_fa'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 158,
   "id": "faa11da3-07ad-4019-bfd7-589342c435aa",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'clearance of',\n",
       " 'clinical benefit to',\n",
       " 'concentrations of',\n",
       " 'discontinuation of',\n",
       " 'dose of',\n",
       " 'dose-adjusted trough concentrations of',\n",
       " 'exposure to',\n",
       " 'half-life time of',\n",
       " 'metabolism of',\n",
       " nan,\n",
       " 'resistance to',\n",
       " 'response to',\n",
       " 'steady-state concentration of',\n",
       " 'time to response to',\n",
       " 'trough concentration of'}"
      ]
     },
     "execution_count": 158,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "set(main_with_var['PD/PK terms'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 159,
   "id": "61e8c91c-c963-4710-82f1-e6ec9f4c8def",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'activity of',\n",
       " 'affinity to',\n",
       " 'catalytic activity of',\n",
       " 'clearance of',\n",
       " 'concentrations of',\n",
       " 'enzyme activity of',\n",
       " 'expression of',\n",
       " 'formation of',\n",
       " 'glucuronidation of',\n",
       " 'half-life of',\n",
       " 'inhibition of',\n",
       " 'metabolism of',\n",
       " nan,\n",
       " 'protein stability of',\n",
       " 'sensitivity to',\n",
       " 'steady-state level of',\n",
       " 'sulfation of',\n",
       " 'transcription of',\n",
       " 'transport of',\n",
       " 'uptake of'}"
      ]
     },
     "execution_count": 159,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "set(main_with_var['Functional terms'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 160,
   "id": "87c61724-3034-413f-b691-6ea8d475ae5d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'age at onset of', 'likelihood of', nan, 'risk of', 'severity of'}"
      ]
     },
     "execution_count": 160,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "set(main_with_var['Side effect/efficacy/other'])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "da232356-d984-4e35-bbe3-e5811b68d172",
   "metadata": {},
   "source": [
    "Assume the last term will vary but hopefully we can also map it to the relevant domain (CHEMBL, EFO, Ensembl).\n",
    "\n",
    "This is a pretty small set of terms for ca. 15000 rows, though I don't think we can assume the vocab won't grow (except the actual direction word, we should be good there)."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "59bcdfc1-98df-4f21-aa2e-487b2d4af3dc",
   "metadata": {},
   "source": [
    "## 3. Direction of effect prototyping"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3d245b86-133c-488b-a580-1ce79c7e83e7",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "237fc62d-e5e8-4df6-a9c9-6d266dc83e73",
   "metadata": {},
   "source": [
    "### To-do's\n",
    "\n",
    "Consistency:\n",
    "* check consistency of allele/genotype representations - SNPs and star alleles\n",
    "    * ensure we can connect these to the alleles table\n",
    "* check consistency of disease/side effect/other? representation for phenotypes\n",
    "    * ensure we can parse and map these if needed\n",
    "\n",
    "Prototyping:\n",
    "* sample schema additions for unified representation\n",
    "* sample extraction"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "daf324bb-3f75-46db-be7c-1cd8ea561964",
   "metadata": {},
   "source": [
    "Specific questions:\n",
    "* Do we care about all of the tables? (for v1)\n",
    "* Do we care about the other columns? (for v1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c60bfd67-58b3-4264-b847-5847f6a14fce",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
